Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cytokinetics, Incorporated (CYTK)
USD82.24
-2.63 (-3.10%)
US NASDAQ Healthcare Biotechnology
Address
350 Oyster Point Boulevard 94080
South San Francisco, CA, US
South San Francisco, CA, US
CEO
Robert I. Blum
Website
cytokinetics.com
IPO
2004-04-26
CIK 1061983 ISIN US23282W6057
Description
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
News Sentiment (7d)
3 articles
- iShares Russell 2000 Value vs. Morningstar Small Cap: Which ETF Suits Your Portfolio Best? Fool - Investing News
- Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026 GlobeNewsWire
- Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure? Zacks Investment Research
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD82.24
-2.63 (-3.10%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.44
Float Shares
119.35M
Free Float %
96.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.34% | +0.40% | +12.13% | +12.90% | +14.18% | +17.74% | +144.40% | +92.07% | +196.51% | +897.47% | -22.56% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (35 ratings, all time)
Buy
Price Targets & DCF
Current price
82.24
Low
83.00
+0.9%
Consensus
99.92
+21.5%
Median
99.00
+20.4%
High
140.00
+70.2%
Ratings Trend (MoM)
86% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 7 | 0 |
| Buy | 11 | 0 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 5 |
115.20
+40.1%
|
| Last Quarter | 9 |
102.78
+25.0%
|
| Last Year | 26 |
93.12
+13.2%
|
| All Time | 48 |
86.08
+4.7%
|
Quality scores
Altman Z-Score
-2.68
Distress
Piotroski F-Score
3 / 9
Average
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+376.6% ★ Q1'26: +1,125.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-24.3% Q1'26: -22.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,050.1% Q1'26: -782.2% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-891.6% Q1'26: -948.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +121.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+7.3% Q1'26: +4.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-1.66× Q1'26: -1.44× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2011 actual |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 15 Rev. Ana. 13 EPS Ana. |
Dec 2027 15 Rev. Ana. 14 EPS Ana. |
Dec 2028 13 Rev. Ana. 13 EPS Ana. |
Dec 2029 12 Rev. Ana. 11 EPS Ana. |
Dec 2030 6 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
4.00M
est: 4.42M (-9.4%)
|
7.56M
est: 9.53M (-20.7%)
|
30.65M
est: 12.09M (+153.5%)
|
46.94M
est: 51.10M (-8.1%)
|
28.66M
est: 30.41M (-5.8%)
|
106.41M
est: 88.95M (+19.6%)
|
13.37M
est: 19.65M (-32.0%)
|
31.50M
est: 27.04M (+16.5%)
|
26.87M
est: 29.38M (-8.5%)
|
55.83M
est: 70.03M (-20.3%)
|
70.43M
est: 20.72M (+239.9%)
|
94.59M
est: 99.32M (-4.8%)
|
7.53M
est: 3.13M (+140.3%)
|
18.47M
est: 3.20M (+476.7%)
|
88.04M
est: 76.88M (+14.5%)
|
101.58M
59.02M – 179.83M
+32.1% YoY
|
387.93M
324.02M – 503.22M
+281.9% YoY
|
877.15M
851.75M – 902.55M
+126.1% YoY
|
1.52B
1.18B – 2.16B
+73.3% YoY
|
2.31B
1.79B – 3.28B
+51.9% YoY
|
| EBITDA |
-46.52M
est: -48.56M (+4.2%)
|
-39.78M
est: -47.28M (+15.9%)
|
-33.28M
est: -24.51M (-35.8%)
|
-14.16M
est: -2.74M (-416.2%)
|
-36.66M
est: -35.24M (-4.0%)
|
14.93M
est: -88.95M (+116.8%)
|
-108.89M
est: -93.05M (-17.0%)
|
-83.49M
est: -85.66M (+2.5%)
|
-93.04M
est: -29.38M (-216.7%)
|
-86.78M
est: -60.33M (-43.8%)
|
-176.35M
est: -151.33M (-16.5%)
|
-329.40M
est: -149.78M (-119.9%)
|
-456.68M
est: -3.13M (-14,471.9%)
|
-493.48M
est: -3.20M (-15,304.4%)
|
-775.27M
est: -76.88M (-908.5%)
|
-101.58M
-179.83M – -59.02M
-32.1% YoY
|
-387.93M
-503.22M – -324.02M
-281.9% YoY
|
-877.15M
-902.55M – -851.75M
-126.1% YoY
|
-1.52B
-2.16B – -1.18B
-73.3% YoY
|
-2.31B
-3.28B – -1.79B
-51.9% YoY
|
| EBIT |
-47.82M
est: -50.13M (+4.6%)
|
-40.37M
est: -48.08M (+16.0%)
|
-33.72M
est: -26.16M (-28.9%)
|
-14.65M
est: -3.93M (-272.4%)
|
-37.25M
est: -36.00M (-3.5%)
|
14.19M
est: -88.95M (+115.9%)
|
-110.79M
est: -96.96M (-14.3%)
|
-84.73M
est: -91.29M (+7.2%)
|
-94.33M
est: -29.38M (-221.1%)
|
-88.61M
est: -67.34M (-31.6%)
|
-185.98M
est: -153.55M (-21.1%)
|
-337.80M
est: -149.96M (-125.3%)
|
-468.58M
est: -3.13M (-14,851.4%)
|
-503.01M
est: -3.20M (-15,601.9%)
|
-784.96M
est: -76.88M (-921.1%)
|
-101.58M
-179.83M – -59.02M
-32.1% YoY
|
-387.93M
-503.22M – -324.02M
-281.9% YoY
|
-877.15M
-902.55M – -851.75M
-126.1% YoY
|
-1.52B
-2.16B – -1.18B
-73.3% YoY
|
-2.31B
-3.28B – -1.79B
-51.9% YoY
|
| Net Income |
-47.86M
est: -50.02M (+4.3%)
|
-41.68M
est: -47.98M (+13.1%)
|
-33.72M
est: -25.65M (-31.5%)
|
-14.65M
est: -3.76M (-289.9%)
|
-37.50M
est: -36.16M (-3.7%)
|
16.45M
est: 125.03M (-86.8%)
|
-127.79M
est: -109.49M (-16.7%)
|
-106.29M
est: -109.44M (+2.9%)
|
-121.69M
est: -227.32M (+46.5%)
|
-127.29M
est: -100.27M (-26.9%)
|
-215.31M
est: -181.31M (-18.8%)
|
-388.96M
est: -178.74M (-117.6%)
|
-526.24M
est: -545.28M (+3.5%)
|
-589.53M
est: -606.31M (+2.8%)
|
-784.96M
est: -829.61M (+5.4%)
|
-826.29M
-888.61M – -539.77M
+0.4% YoY
|
-630.09M
-663.92M – -379.04M
+23.7% YoY
|
-295.29M
-445.32M – -102.42M
+53.1% YoY
|
101.29M
71.99M – 156.81M
+134.3% YoY
|
503.83M
358.08M – 780.04M
+397.4% YoY
|
| SGA |
13.59M
est: 34.37M (-60.5%)
|
11.72M
est: 74.17M (-84.2%)
|
15.09M
est: 94.10M (-84.0%)
|
17.27M
est: 29.93M (-42.3%)
|
19.67M
est: 19.59M (+0.4%)
|
27.82M
est: 60.27M (-53.8%)
|
36.47M
est: 152.92M (-76.2%)
|
31.28M
est: 210.45M (-85.1%)
|
39.61M
est: 228.63M (-82.7%)
|
52.82M
est: 51.57M (+2.4%)
|
96.80M
est: 161.24M (-40.0%)
|
177.98M
est: 772.97M (-77.0%)
|
173.61M
est: 25.82M (+572.3%)
|
215.31M
est: 26.39M (+715.8%)
|
284.27M
est: 633.40M (-55.1%)
|
836.96M
486.29M – 1.48B
+32.1% YoY
|
3.20B
2.67B – 4.15B
+281.9% YoY
|
7.23B
7.02B – 7.44B
+126.1% YoY
|
12.52B
9.74B – 17.80B
+73.3% YoY
|
19.02B
14.79B – 27.04B
+51.9% YoY
|
| EPS |
-4.06
est: -4.35 (+6.6%)
|
-2.15
est: -3.32 (+35.2%)
|
-1.24
est: -1.61 (+22.7%)
|
-0.41
est: -1.66 (+75.2%)
|
-0.97
est: -1.03 (+5.5%)
|
0.41
est: -0.11 (+477.6%)
|
-2.59
est: -2.40 (-8.0%)
|
-1.95
est: -1.94 (-0.7%)
|
-2.59
est: -2.03 (-27.6%)
|
-1.97
est: -1.71 (-15.2%)
|
-2.80
est: -3.26 (+14.2%)
|
-4.33
est: -4.06 (-6.6%)
|
-5.45
est: -5.36 (-1.7%)
|
-5.26
est: -5.19 (-1.4%)
|
-6.54
est: -6.49 (-0.8%)
|
-6.45
-7.40 – -4.49
+0.6% YoY
|
-4.61
-5.53 – -3.16
+28.5% YoY
|
-1.88
-3.71 – -0.85
+59.2% YoY
|
0.84
0.60 – 1.31
+144.8% YoY
|
4.20
2.98 – 6.49
+397.4% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-05-07 | Wells Fargo | Overweight | Overweight | Maintain |
| 2026-05-06 | Morgan Stanley | Overweight | Overweight | Maintain |
| 2026-05-05 | Needham | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-361.87M
OE per share TTM
-2.97
Owner's Yield
-3.92%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
216.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
79
Total invested
163.66M
Insider transactions (90d)
9
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | (1) BlackRock, Inc. | 15.25M | 13.00% | — | — | 15.25M | — | HC | Delaware | 2024-10-23 | ↗ |
| 2 | 85-4328500 | 9.69M | 8.20% | 9.67M | — | 9.69M | — | IA | Maryland | 2024-11-14 | ↗ |
| 3 | The Vanguard Group - 23-1945930 | 8.74M | 10.30% | — | 132.6K | 8.53M | 207.5K | IA | Pennsylvania | 2022-04-08 | ↗ |
| 4 | Abigail P. Johnson | 8.49M | 11.83% | — | — | 8.49M | — | IN | Delaware | 2021-07-12 | ↗ |
| 5 | FMR LLC | 8.49M | 11.83% | 353.6K | — | 8.49M | — | HC | Delaware | 2021-07-12 | ↗ |
| 6 | Wellington Group Holdings LLP | 6.54M | 6.91% | — | 6.05M | — | — | HC | Massachusetts | 2023-02-06 | ↗ |
| 7 | Wellington Investment Advisors Holdings LLP | 6.54M | 6.91% | — | 6.05M | — | — | HC | Massachusetts | 2023-02-06 | ↗ |
| 8 | Wellington Management Group LLP | 6.54M | 6.91% | — | 6.05M | — | — | HC | Massachusetts | 2023-02-06 | ↗ |
| 9 | Wellington Management Company LLP | 6.31M | 6.67% | — | 6.02M | — | — | IA | Massachusetts | 2023-02-06 | ↗ |
| 10 | STATE STREET CORPORATION | 3.99M | 4.75% | — | 3.83M | — | 3.99M | HC | BOSTON MASSACHUSETTS | 2022-02-09 | ↗ |
| 11 | EASTERN CAPITAL LIMITED | 3.06M | 4.30% | — | 3.06M | — | 3.06M | CO | CAYMAN ISLANDS | 2021-02-19 | ↗ |
| 12 | KENNETH B. DART | 3.06M | 4.30% | — | 3.06M | — | 3.06M | IN | CAYMAN ISLANDS | 2021-02-19 | ↗ |
| 13 | PORTFOLIO SERVICES LTD. | 3.06M | 4.30% | — | 3.06M | — | 3.06M | CO | CAYMAN ISLANDS | 2021-02-19 | ↗ |
| 14 | BVF Inc. | 2.73M | 3.90% | — | — | — | 2.73M | CO | Delaware | 2021-01-13 | ↗ |
| 15 | BVF Partners L.P. | 2.73M | 3.90% | — | — | — | 2.73M | IA, PN | Delaware | 2021-01-13 | ↗ |
| 16 | Mark N. Lampert | 2.73M | 3.90% | — | — | — | 2.73M | IN | Delaware | 2021-01-13 | ↗ |
| 17 | BVF GP HOLDINGS LLC | 2.50M | 3.50% | — | — | — | 2.50M | OO | Delaware | 2021-01-13 | ↗ |
| 18 | DRIEHAUS CAPITAL MANAGEMENT LLC | 2.33M | 2.77% | — | 2.33M | — | 2.33M | IA | Delaware USA | 2022-02-14 | ↗ |
| 19 | BVF I GP LLC | 1.44M | 2.00% | — | — | — | 1.44M | OO | Delaware | 2021-01-13 | ↗ |
| 20 | Biotechnology Value Fund, L.P. | 1.44M | 2.00% | — | — | — | 1.44M | PN | Delaware | 2021-01-13 | ↗ |
| 21 | Point72 Asset Management, L.P. | 1.17M | 4.00% | — | 1.17M | — | 1.17M | PN | Delaware | 2021-02-16 | ↗ |
| 22 | BVF II GP LLC | 1.06M | 1.50% | — | — | — | 1.06M | OO | Delaware | 2021-01-13 | ↗ |
| 23 | Biotechnology Value Fund II, L.P. | 1.06M | 1.50% | — | — | — | 1.06M | PN | Delaware | 2021-01-13 | ↗ |
| 24 | BVF Partners OS Ltd. | 174.2K | 1.00% | — | — | — | 174.2K | CO | Delaware | 2021-01-13 | ↗ |
| 25 | Biotechnology Value Trading Fund OS LP | 174.2K | 1.00% | — | — | — | 174.2K | PN | Delaware | 2021-01-13 | ↗ |
| 26 | Dr. Jeffrey R. Jay, M.D. | 160.1K | 0.27% | — | 160.1K | — | — | HC, IN | USA | 2020-02-14 | ↗ |
| 27 | Mr. David Kroin | 160.1K | 0.27% | — | 160.1K | — | — | HC, IN | USA | 2020-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
79
-393 vs prev Q
New positions
17
Closed positions
373
Increased
41
Reduced
22
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | T. ROWE PRICE INVESTMENT MANAGEMENT, INC. | 17.72M -1.4M (-7.1%) | 1.13B +77.0M (+7.3%) | 14.77% -1.207 pp | 0.71% +0.070 pp | USD47.13 +34.8% | 13 qtrs — |
| 2 | BLACKROCK, INC. | 16.40M +869.4K (+5.6%) | 1.04B +188.5M (+22.1%) | 13.66% +0.668 pp | 0.02% +0.003 pp | USD53.09 +19.7% | 6 qtrs — |
| 3 | FMR LLC | 12.81M -283.9K (-2.2%) | 813.80M +94.3M (+13.1%) | 10.67% -0.285 pp | 0.04% +0.004 pp | USD36.07 +76.2% | 50 qtrs — |
| 4 | VANGUARD GROUP INC | 12.05M +191.3K (+1.6%) | 765.54M +113.9M (+17.5%) | 10.04% +0.116 pp | 0.01% +0.001 pp | USD33.58 +89.2% | 50 qtrs — |
| 5 | WELLINGTON MANAGEMENT GROUP LLP | 7.94M +528.5K (+7.1%) | 504.32M +97.1M (+23.9%) | 6.62% +0.413 pp | 0.09% +0.017 pp | USD47.43 +34.0% | 23 qtrs — |
| 6 | STATE STREET CORP | 5.83M +208.0K (+3.7%) | 370.14M +61.4M (+19.9%) | 4.86% +0.153 pp | 0.01% +0.002 pp | USD38.17 +66.5% | 51 qtrs — |
| 7 | DEEP TRACK CAPITAL, LP | 3.34M -963.0K (-22.4%) | 212.03M -24.3M (-10.3%) | 2.78% -0.818 pp | 3.78% -2.815 pp | USD46.35 +37.1% | 9 qtrs — |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 3.06M +15.8K (+0.5%) | 194.21M +27.1M (+16.2%) | 2.55% +0.002 pp | 0.01% +0.001 pp | USD35.16 +80.7% | 51 qtrs — |
| 9 | BANK OF AMERICA CORP /DE/ | 2.94M -120.6K (-3.9%) | 186.88M +18.6M (+11.1%) | 2.45% -0.112 pp | 0.01% +0.002 pp | USD44.23 +43.7% | 50 qtrs — |
| 10 | RTW INVESTMENTS, LP | 2.72M +— (+0.0%) | 172.90M +23.3M (+15.6%) | 2.27% -0.010 pp | 1.73% -0.111 pp | USD29.00 +119.1% | 22 qtrs — |
| 11 | POLAR CAPITAL HOLDINGS PLC | 2.42M -360.3K (-12.9%) | 153.93M +982.9K (+0.6%) | 2.02% -0.311 pp | 0.59% -0.141 pp | USD39.73 +59.9% | 21 qtrs — |
| 12 | GOLDMAN SACHS GROUP INC | 2.37M +737.0K (+45.1%) | 150.70M +60.9M (+67.7%) | 1.98% +0.608 pp | 0.02% +0.008 pp | USD53.12 +19.6% | 50 qtrs — |
| 13 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.93M -436.7K (-18.5%) | 122.64M -7.4M (-5.7%) | 1.61% -0.373 pp | 0.01% -0.001 pp | USD63.93 -0.6% | 22 qtrs — |
| 14 | WOODLINE PARTNERS LP | 1.65M +703.0 (+0.0%) | 104.74M +14.2M (+15.7%) | 1.37% -0.005 pp | 0.41% -0.020 pp | USD54.17 +17.3% | 9 qtrs — |
| 15 | JPMORGAN CHASE & CO | 1.41M -130.1K (-8.4%) | 89.77M +5.0M (+5.9%) | 1.18% -0.114 pp | 0.01% +0.001 pp | USD54.45 +16.7% | 33 qtrs — |
| 16 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.38M +9.6K (+0.7%) | 87.90M +12.4M (+16.4%) | 1.15% +0.003 pp | 0.01% +0.002 pp | USD37.70 +68.5% | 50 qtrs — |
| 17 | NORTHERN TRUST CORP | 1.38M -26.0K (-1.9%) | 87.74M +10.4M (+13.5%) | 1.15% -0.027 pp | 0.01% +0.001 pp | USD28.23 +125.1% | 50 qtrs — |
| 18 | MORGAN STANLEY | 1.27M -255.9K (-16.8%) | 80.40M -3.2M (-3.8%) | 1.05% -0.219 pp | 0.00% 0.000 pp | USD54.76 +16.0% | 50 qtrs — |
| 19 | CAPITAL INTERNATIONAL INVESTORS | 1.18M +— (+0.0%) | 74.90M +10.1M (+15.6%) | 0.98% -0.004 pp | 0.01% +0.001 pp | USD46.69 +36.1% | 5 qtrs — |
| 20 | CITADEL ADVISORS LLC | 1.16M -223.1K (-16.1%) | 73.89M -2.3M (-3.0%) | 0.97% -0.191 pp | 0.01% -0.001 pp | USD49.71 +27.8% | 48 qtrs — |
| 21 | UBS GROUP AG | 1.13M -671.8K (-37.3%) | 71.89M -27.2M (-27.5%) | 0.94% -0.567 pp | 0.01% -0.004 pp | USD41.46 +53.3% | 45 qtrs — |
| 22 | ARMISTICE CAPITAL, LLC | 992.8K -204.1K (-17.1%) | 63.08M -2.7M (-4.1%) | 0.83% -0.175 pp | 0.75% -0.225 pp | USD60.48 +5.1% | 8 qtrs — |
| 23 | PRINCIPAL FINANCIAL GROUP INC | 976.9K -197.6K (-16.8%) | 62.07M -2.5M (-3.8%) | 0.81% -0.169 pp | 0.03% -0.001 pp | USD32.66 +94.5% | 35 qtrs — |
| 24 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 934.6K +44.2K (+5.0%) | 59.39M +10.4M (+21.3%) | 0.78% +0.034 pp | 1.60% +0.129 pp | USD42.36 +50.0% | 3 qtrs — |
| 25 | BANK OF NEW YORK MELLON CORP | 854.3K -14.9K (-1.7%) | 54.28M +6.5M (+13.6%) | 0.71% -0.016 pp | 0.01% +0.000 pp | USD33.24 +91.2% | 50 qtrs — |
| 26 | JANE STREET GROUP, LLC | 840.5K +239.2K (+39.8%) | 53.41M +20.4M (+61.6%) | 0.70% +0.197 pp | 0.01% +0.003 pp | USD46.79 +35.8% | 6 qtrs — |
| 27 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 827.9K +42.9K (+5.5%) | 52.60M +9.5M (+21.9%) | 0.69% +0.033 pp | 0.06% -0.051 pp | USD37.90 +67.7% | 21 qtrs — |
| 28 | FISHER ASSET MANAGEMENT, LLC | 822.9K +61.3K (+8.0%) | 52.29M +10.4M (+24.9%) | 0.69% +0.048 pp | 0.02% +0.003 pp | USD69.09 -8.0% | 9 qtrs — |
| 29 | NORGES BANK | 807.1K +807.1K (+100.0%) | 51.28M +51.3M (+100.0%) | 0.67% +0.673 pp | 0.01% +0.006 pp | USD63.54 +0.0% | 1 qtrs NEW |
| 30 | AFFINITY ASSET ADVISORS, LLC | 800.0K +450.0K (+128.6%) | 50.83M +31.6M (+164.3%) | 0.67% +0.374 pp | 2.90% +1.221 pp | USD59.79 +6.3% | 2 qtrs — |
| 31 | PICTET ASSET MANAGEMENT HOLDING SA | 757.6K -388.0K (-33.9%) | 48.02M -14.8M (-23.6%) | 0.63% -0.328 pp | 0.05% -0.014 pp | USD41.15 +54.4% | 10 qtrs — |
| 32 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 753.6K -264.2K (-26.0%) | 47.88M -8.1M (-14.4%) | 0.63% -0.224 pp | 0.01% -0.001 pp | USD46.85 +35.6% | 31 qtrs — |
| 33 | NATIONALE-NEDERLANDEN POWSZECHNE TOWARZYSTWO EMERYTALNE S.A. | 748.0K -444.5K (-37.3%) | 47.53M -18.0M (-27.5%) | 0.62% -0.375 pp | 4.22% -0.846 pp | USD36.95 +72.0% | 5 qtrs — |
| 34 | BROWN ADVISORY INC | 731.2K -181.0K (-19.8%) | 46.46M -3.7M (-7.3%) | 0.61% -0.154 pp | 0.06% 0.000 pp | USD65.74 -3.3% | 8 qtrs — |
| 35 | MELQART ASSET MANAGEMENT (UK) LTD | 622.9K -160.9K (-20.5%) | 39.58M -3.5M (-8.1%) | 0.52% -0.137 pp | 3.90% -1.851 pp | USD57.46 +10.6% | 8 qtrs — |
| 36 | BNP PARIBAS ARBITRAGE, SNC | 579.9K +332.4K (+134.3%) | 36.84M +23.2M (+170.9%) | 0.48% +0.276 pp | 0.02% +0.009 pp | USD53.69 +18.3% | 49 qtrs — |
| 37 | AMERIPRISE FINANCIAL INC | 545.8K -18.7K (-3.3%) | 34.68M +3.7M (+11.8%) | 0.45% -0.018 pp | 0.01% +0.001 pp | USD47.37 +34.1% | 35 qtrs — |
| 38 | TD ASSET MANAGEMENT INC | 544.0K -127.8K (-19.0%) | 34.57M -2.4M (-6.4%) | 0.45% -0.109 pp | 0.03% -0.002 pp | USD54.14 +17.4% | 17 qtrs — |
| 39 | ADAR1 CAPITAL MANAGEMENT, LLC | 540.2K +21.2K (+4.1%) | 34.32M +5.8M (+20.3%) | 0.45% +0.016 pp | 2.52% -0.158 pp | USD52.95 +20.0% | 9 qtrs — |
| 40 | QUBE RESEARCH & TECHNOLOGIES LTD | 537.3K +528.2K (+5,844.6%) | 34.14M +33.6M (+6,772.7%) | 0.45% +0.440 pp | 0.03% +0.034 pp | USD63.20 +0.5% | 12 qtrs — |
| 41 | INTEGRAL HEALTH ASSET MANAGEMENT, LLC | 500.0K -250.0K (-33.3%) | 31.77M -9.5M (-22.9%) | 0.42% -0.211 pp | 1.58% -1.211 pp | USD40.35 +57.5% | 3 qtrs — |
| 42 | CAPTION MANAGEMENT, LLC | 486.3K +191.2K (+64.8%) | 30.90M +14.7M (+90.5%) | 0.41% +0.158 pp | 0.21% +0.085 pp | USD55.49 +14.5% | 10 qtrs — |
| 43 | FEDERATED HERMES, INC. | 483.7K +457.9K (+1,775.1%) | 30.73M +29.3M (+2,067.8%) | 0.40% +0.382 pp | 0.05% +0.049 pp | USD63.23 +0.5% | 8 qtrs — |
| 44 | ABRDN PLC | 483.1K -444.8K (-47.9%) | 30.69M -20.3M (-39.8%) | 0.40% -0.374 pp | 0.05% -0.033 pp | USD49.84 +27.5% | 9 qtrs — |
| 45 | EVENTIDE ASSET MANAGEMENT, LLC | 479.6K +309.5K (+181.9%) | 30.47M +21.1M (+225.9%) | 0.40% +0.257 pp | 0.48% +0.322 pp | USD56.58 +12.3% | 13 qtrs — |
| 46 | GW&K INVESTMENT MANAGEMENT, LLC | 472.4K +291.7K (+161.5%) | 30.02M +20.1M (+202.3%) | 0.39% +0.243 pp | 0.26% +0.172 pp | USD60.26 +5.4% | 2 qtrs — |
| 47 | FORESITE CAPITAL MANAGEMENT IV, LLC | 458.3K +— (+0.0%) | 29.12M +3.9M (+15.6%) | 0.38% -0.002 pp | 12.68% -1.117 pp | USD54.96 +15.6% | 2 qtrs — |
| 48 | AMERICAN CENTURY COMPANIES INC | 443.9K +14.7K (+3.4%) | 28.21M +4.6M (+19.6%) | 0.37% +0.011 pp | 0.01% +0.002 pp | USD38.95 +63.1% | 18 qtrs — |
| 49 | ALLIANCEBERNSTEIN L.P. | 413.0K +177.6K (+75.4%) | 26.24M +13.3M (+102.8%) | 0.34% +0.147 pp | 0.01% +0.004 pp | USD66.82 -4.9% | 50 qtrs — |
| 50 | FRANKLIN RESOURCES INC | 410.0K +265.0 (+0.1%) | 26.05M +3.5M (+15.7%) | 0.34% -0.001 pp | 0.01% +0.001 pp | USD40.64 +56.3% | 18 qtrs — |
| 51 | GROUP ONE TRADING, L.P. | 407.3K +219.3K (+116.7%) | 25.88M +15.5M (+150.5%) | 0.34% +0.182 pp | 0.05% +0.027 pp | USD51.49 +23.4% | 4 qtrs — |
| 52 | SARISSA CAPITAL MANAGEMENT LP | 396.4K -192.0K (-32.6%) | 25.18M -7.2M (-22.1%) | 0.33% -0.162 pp | 11.30% -6.627 pp | USD59.65 +6.5% | 8 qtrs — |
| 53 | GILDER GAGNON HOWE & CO LLC | 385.8K -3.2K (-0.8%) | 24.51M +3.1M (+14.7%) | 0.32% -0.004 pp | 0.26% +0.041 pp | USD44.71 +42.1% | 14 qtrs — |
| 54 | DAFNA CAPITAL MANAGEMENT LLC | 371.0K -23.9K (-6.1%) | 23.57M +1.9M (+8.6%) | 0.31% -0.021 pp | 5.48% +0.113 pp | USD33.50 +89.7% | 18 qtrs — |
| 55 | NUVEEN, LLC | 369.3K -1.6K (-0.4%) | 23.46M +3.1M (+15.1%) | 0.31% -0.003 pp | 0.01% +0.001 pp | USD42.72 +48.7% | 4 qtrs — |
| 56 | E. OHMAN J:OR ASSET MANAGEMENT AB | 363.0K -44.1K (-10.8%) | 23.06M +691.9K (+3.1%) | 0.30% -0.038 pp | 0.54% +0.010 pp | USD38.82 +63.7% | 4 qtrs — |
| 57 | BALYASNY ASSET MANAGEMENT L.P. | 358.5K -2.1K (-0.6%) | 22.78M +3.0M (+14.9%) | 0.30% -0.003 pp | 0.03% +0.004 pp | USD54.96 +15.6% | 2 qtrs — |
| 58 | RHUMBLINE ADVISERS | 357.0K -28.8K (-7.5%) | 22.68M +1.5M (+7.0%) | 0.30% -0.025 pp | 0.02% +0.001 pp | USD31.84 +99.6% | 51 qtrs — |
| 59 | BARCLAYS PLC | 343.5K -33.5K (-8.9%) | 21.82M +1.9M (+9.6%) | 0.29% -0.029 pp | 0.01% +0.000 pp | USD43.13 +47.3% | 50 qtrs — |
| 60 | EXODUSPOINT CAPITAL MANAGEMENT, LP | 343.1K +343.1K (+100.0%) | 21.80M +21.8M (+100.0%) | 0.29% +0.286 pp | 0.17% +0.171 pp | USD63.54 +0.0% | 1 qtrs NEW |
| 61 | GSK PLC | 340.4K +340.4K (+100.0%) | 21.63M +21.6M (+100.0%) | 0.28% +0.284 pp | 2.71% +2.707 pp | USD63.54 +0.0% | 1 qtrs NEW |
| 62 | MARSHALL WACE, LLP | 337.0K +158.1K (+88.3%) | 21.41M +11.6M (+117.7%) | 0.28% +0.131 pp | 0.02% +0.010 pp | USD59.29 +7.2% | 22 qtrs — |
| 63 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 327.2K -169.5K (-34.1%) | 20.79M -6.5M (-23.8%) | 0.27% -0.143 pp | 0.01% -0.002 pp | USD46.70 +36.1% | 7 qtrs — |
| 64 | FIRST TURN MANAGEMENT, LLC | 325.7K +70.9K (+27.8%) | 20.69M +6.7M (+47.8%) | 0.27% +0.058 pp | 2.36% +0.262 pp | USD56.83 +11.8% | 2 qtrs — |
| 65 | LOGOS GLOBAL MANAGEMENT LP | 300.0K +300.0K (+100.0%) | 19.06M +19.1M (+100.0%) | 0.25% +0.250 pp | 1.15% +1.152 pp | USD63.54 +0.0% | 1 qtrs NEW |
| 66 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 278.4K +— (+0.0%) | 17.69M +2.4M (+15.6%) | 0.23% -0.001 pp | 0.27% +0.030 pp | USD34.15 +86.1% | 3 qtrs — |
| 67 | TWO SIGMA INVESTMENTS, LP | 274.0K +274.0K (+100.0%) | 17.41M +17.4M (+100.0%) | 0.23% +0.228 pp | 0.02% +0.025 pp | USD63.54 +0.0% | 1 qtrs NEW |
| 68 | CATALIO CAPITAL MANAGEMENT, LP | 258.4K -193.2K (-42.8%) | 16.42M -8.4M (-33.9%) | 0.22% -0.163 pp | 2.90% -1.687 pp | USD45.22 +40.5% | 5 qtrs — |
| 69 | JANUS HENDERSON GROUP PLC | 256.2K +206.6K (+416.9%) | 16.28M +13.6M (+497.5%) | 0.21% +0.172 pp | 0.01% +0.006 pp | USD59.23 +7.3% | 18 qtrs — |
| 70 | NOMURA HOLDINGS INC | 254.2K +5.0K (+2.0%) | 16.15M +2.5M (+17.9%) | 0.21% +0.003 pp | 0.02% +0.000 pp | USD54.70 +16.2% | 9 qtrs — |
| 71 | UBS ASSET MANAGEMENT AMERICAS INC | 235.0K -3.3K (-1.4%) | 14.94M +1.8M (+14.0%) | 0.20% -0.004 pp | 0.00% +0.000 pp | USD41.14 +54.4% | 31 qtrs — |
| 72 | AQR CAPITAL MANAGEMENT LLC | 236.9K -276.4K (-53.8%) | 14.77M -13.4M (-47.6%) | 0.20% -0.232 pp | 0.01% -0.010 pp | USD40.49 +56.9% | 26 qtrs — |
| 73 | MILLENNIUM MANAGEMENT LLC | 225.5K -117.1K (-34.2%) | 14.33M -4.5M (-23.9%) | 0.19% -0.099 pp | 0.01% -0.002 pp | USD38.92 +63.3% | 50 qtrs — |
| 74 | SWISS NATIONAL BANK | 224.2K +4.3K (+2.0%) | 14.25M +2.2M (+17.9%) | 0.19% +0.003 pp | 0.01% +0.002 pp | USD33.14 +91.7% | 35 qtrs — |
| 75 | HANDELSBANKEN FONDER AB | 205.8K -28.7K (-12.2%) | 13.08M +189.0K (+1.5%) | 0.17% -0.025 pp | 0.04% -0.001 pp | USD53.11 +19.6% | 21 qtrs — |
| 76 | INVESCO LTD. | 204.9K +47.6K (+30.3%) | 13.02M +4.4M (+50.6%) | 0.17% +0.039 pp | 0.00% +0.001 pp | USD50.71 +25.3% | 43 qtrs — |
| 77 | MIRADOR CAPITAL PARTNERS LP | 198.6K +1.2K (+0.6%) | 12.62M +1.8M (+16.3%) | 0.17% +0.000 pp | 1.73% +0.192 pp | USD40.72 +56.0% | 25 qtrs — |
| 78 | ROSALIND ADVISORS, INC. | 195.0K -205.0K (-51.2%) | 12.39M -9.6M (-43.6%) | 0.16% -0.172 pp | 4.36% -3.159 pp | USD33.04 +92.3% | 3 qtrs — |
| 79 | PINNACLE ASSOCIATES LTD | 191.0K -10.5K (-5.2%) | 12.14M +1.1M (+9.6%) | 0.16% -0.010 pp | 0.16% +0.009 pp | USD18.12 +250.7% | 34 qtrs — |
| 80 | SEGALL BRYANT & HAMILL, LLC | 189.5K +8.5K (+4.7%) | 12.04M +2.1M (+21.0%) | 0.16% +0.006 pp | 0.16% +0.030 pp | USD53.60 +18.5% | 7 qtrs — |
| 81 | CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM | 189.4K +39.0K (+25.9%) | 12.03M +3.8M (+45.6%) | 0.16% +0.032 pp | 0.01% +0.002 pp | USD51.17 +24.2% | 14 qtrs — |
| 82 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 190.8K -1.1K (-0.6%) | 11.96M +1.4M (+13.4%) | 0.16% -0.002 pp | 0.01% +0.001 pp | USD52.94 +20.0% | 50 qtrs — |
| 83 | DEUTSCHE BANK AG\ | 175.8K +10.2K (+6.2%) | 11.17M +2.1M (+22.8%) | 0.15% +0.008 pp | 0.00% +0.001 pp | USD59.80 +6.3% | 50 qtrs — |
| 84 | HUDSON BAY CAPITAL MANAGEMENT LP | 175.4K -6.8K (-3.7%) | 11.14M +1.1M (+11.3%) | 0.15% -0.006 pp | 0.04% +0.004 pp | USD52.53 +21.0% | 11 qtrs — |
| 85 | TWO SIGMA ADVISERS, LP | 174.7K +174.7K (+100.0%) | 11.10M +11.1M (+100.0%) | 0.15% +0.146 pp | 0.02% +0.022 pp | USD63.54 +0.0% | 1 qtrs NEW |
| 86 | IKARIAN CAPITAL, LLC | 172.7K -50.0K (-22.5%) | 10.97M -1.3M (-10.3%) | 0.14% -0.043 pp | 0.86% -0.379 pp | USD58.18 +9.2% | 9 qtrs — |
| 87 | RENAISSANCE TECHNOLOGIES LLC | 172.1K -117.9K (-40.7%) | 10.93M -5.0M (-31.4%) | 0.14% -0.099 pp | 0.02% -0.004 pp | USD55.48 +14.5% | 9 qtrs — |
| 88 | LEGAL & GENERAL GROUP PLC | 168.6K -11.1K (-6.2%) | 10.71M +838.4K (+8.5%) | 0.14% -0.010 pp | 0.00% +0.000 pp | USD30.21 +110.3% | 41 qtrs — |
| 89 | CHECKPOINT CAPITAL L.P. | 166.8K +129.2K (+343.8%) | 10.60M +8.5M (+413.1%) | 0.14% +0.108 pp | 3.31% +2.619 pp | USD61.61 +3.1% | 2 qtrs — |
| 90 | WELLS FARGO & COMPANY/MN | 161.6K +64.1K (+65.8%) | 10.27M +4.9M (+91.6%) | 0.13% +0.053 pp | 0.00% +0.001 pp | USD50.13 +26.8% | 50 qtrs — |
| 91 | STEMPOINT CAPITAL LP | 147.0K +147.0K (+100.0%) | 9.34M +9.3M (+100.0%) | 0.12% +0.123 pp | 1.60% +1.601 pp | USD63.54 +0.0% | 1 qtrs NEW |
| 92 | RETIREMENT SYSTEMS OF ALABAMA | 146.7K +2.0K (+1.4%) | 9.32M +1.4M (+17.2%) | 0.12% +0.001 pp | 0.03% +0.004 pp | USD69.66 -8.8% | 8 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.65
Neutral
Ratio by volume
0.38
Bearish
Buys
15
Sells
23
Shares acquired
78.8K
Shares disposed
209.3K
Cash buys
—
Cash sales
14.00
Net activity
-130,489
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-05 | WIERENGA WENDELL | Director | M-Exempt | D | Non-Qualified Stock Option (Right to Buy) | 4,032 | 12.40 | 50.0K | 0 | D | ↗ |
| 2026-05-05 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 3,500 | 7.80 | 27.3K | 157,402 | D | ↗ |
| 2026-05-05 | Lee Sung | Officer | S-Sale | D | Common Stock | 23,906 | 76.87 | 1.84M | 63,221 | D | ↗ |
| 2026-05-05 | HENDERSON JOHN T | Director | M-Exempt | D | Non-Qualified Stock Option (Right to Buy) | 20,000 | 7.61 | 152.2K | 0 | D | ↗ |
| 2026-05-05 | Callos Andrew | Officer | S-Sale | D | Common Stock | 11,333 | 77.25 | 875.5K | 58,555 | D | ↗ |
| 2026-05-01 | Callos Andrew | Officer | M-Exempt | A | Common Stock | 15,857 | 37.63 | 596.7K | 74,412 | D | ↗ |
| 2026-04-30 | Callos Andrew | Officer | S-Sale | D | Common Stock | 15,000 | 63.26 | 948.9K | 58,555 | D | ↗ |
| 2026-04-29 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 7,500 | 59.62 | 447.2K | 407,830 | D | ↗ |
| 2026-04-21 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 3,500 | 7.80 | 27.3K | 157,402 | D | ↗ |
| 2026-04-15 | Wysenski Nancy | Director | A-Award | A | Common Stock | 95 | 65.37 | 6.2K | 31,066 | D | ↗ |
| 2026-04-15 | WIERENGA WENDELL | Director | A-Award | A | Common Stock | 95 | 65.37 | 6.2K | 32,637 | D | ↗ |
| 2026-04-15 | Kaye Edward M. MD | Director | A-Award | A | Common Stock | 191 | 65.37 | 12.5K | 10,365 | D | ↗ |
| 2026-04-15 | Harrington Robert Arthur | Director | A-Award | A | Common Stock | 191 | 65.37 | 12.5K | 18,930 | D | ↗ |
| 2026-04-15 | HENDERSON JOHN T | Director | A-Award | A | Common Stock | 325 | 65.37 | 21.2K | 75,237 | D | ↗ |
| 2026-04-15 | Daly James M | Director | A-Award | A | Common Stock | 191 | 65.37 | 12.5K | 388 | D | ↗ |
| 2026-04-15 | Callos Andrew | Officer | S-Sale | D | Common Stock | 7,449 | 66.02 | 491.8K | 58,555 | D | ↗ |
| 2026-04-15 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 7,500 | 65.38 | 490.4K | 415,330 | D | ↗ |
| 2026-04-07 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 3,500 | 7.80 | 27.3K | 157,402 | D | ↗ |
| 2026-04-01 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 7,500 | 66.63 | 499.7K | 422,830 | D | ↗ |
| 2026-03-31 | Callos Andrew | Officer | S-Sale | D | Common Stock | 3,639 | 65.00 | 236.5K | 66,004 | D | ↗ |
| 2026-03-18 | Callos Andrew | Officer | S-Sale | D | Common Stock | 1,930 | 62.07 | 119.8K | 78,185 | D | ↗ |
| 2026-03-17 | Malik Fady Ibraham | Officer | S-Sale | D | Common Stock | 4,397 | 62.15 | 273.3K | 153,902 | D | ↗ |
| 2026-03-17 | Lee Sung | Officer | S-Sale | D | Common Stock | 4,935 | 62.15 | 306.7K | 87,127 | D | ↗ |
| 2026-03-17 | Callos Andrew | Officer | S-Sale | D | Common Stock | 5,626 | 62.15 | 349.7K | 74,489 | D | ↗ |
| 2026-03-17 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 23,928 | 62.15 | 1.49M | 430,330 | D | ↗ |
| 2026-03-16 | Callos Andrew | Officer | S-Sale | D | Common Stock | 1,709 | 61.03 | 104.3K | 46,149 | D | ↗ |
| 2026-03-15 | Malik Fady Ibraham | Officer | A-Award | A | Common Stock | 27,306 | 0.00 | — | 165,935 | D | ↗ |
| 2026-03-15 | Lee Sung | Officer | A-Award | A | Common Stock | 20,646 | 0.00 | — | 92,062 | D | ↗ |
| 2026-03-15 | Hessekiel Jeffrey | Officer | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 22,820 | 60.06 | 1.37M | 22,820 | D | ↗ |
| 2026-03-15 | Callos Andrew | Officer | A-Award | A | Common Stock | 13,320 | 0.00 | — | 81,824 | D | ↗ |
| 2026-03-15 | Blum Robert I | Director / Officer | A-Award | A | Common Stock | 75,258 | 0.00 | — | 466,931 | D | ↗ |
| 2026-03-09 | Malik Fady Ibraham | Officer | S-Sale | D | Common Stock | 2,907 | 60.72 | 176.5K | 138,629 | D | ↗ |
| 2026-03-09 | Callos Andrew | Officer | S-Sale | D | Common Stock | 2,582 | 60.72 | 156.8K | 47,858 | D | ↗ |
| 2026-03-09 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 7,931 | 60.72 | 481.6K | 391,673 | D | ↗ |
| 2026-03-05 | Callos Andrew | Officer | M-Exempt | A | Common Stock | 15,000 | 23.26 | 348.9K | 65,440 | D | ↗ |
| 2026-03-02 | PARSHALL B LYNNE | Director | S-Sale | D | Common Stock | 5,000 | 61.21 | 306.1K | 17,933 | D | ↗ |
| 2026-03-02 | Callos Andrew | Officer | M-Exempt | A | Common Stock | 886 | 37.63 | 33.3K | 51,326 | D | ↗ |
| 2026-02-05 | Callos Andrew | Officer | M-Exempt | D | Non-Qualified Stock Option (Right to Buy) | 15,000 | 23.26 | 348.9K | 84,000 | D | ↗ |
| 2026-02-02 | Callos Andrew | Officer | M-Exempt | A | Common Stock | 886 | 37.63 | 33.3K | 51,326 | D | ↗ |
| 2026-01-15 | Wysenski Nancy | Director | A-Award | A | Common Stock | 98 | 63.44 | 6.2K | 30,971 | D | ↗ |
| 2026-01-15 | WIERENGA WENDELL | Director | A-Award | A | Common Stock | 98 | 63.44 | 6.2K | 32,542 | D | ↗ |
| 2026-01-15 | Kaye Edward M. MD | Director | A-Award | A | Common Stock | 197 | 63.44 | 12.5K | 10,174 | D | ↗ |
| 2026-01-15 | Harrington Robert Arthur | Director | A-Award | A | Common Stock | 197 | 63.44 | 12.5K | 18,739 | D | ↗ |
| 2026-01-15 | HENDERSON JOHN T | Director | A-Award | A | Common Stock | 334 | 63.44 | 21.2K | 74,912 | D | ↗ |
| 2026-01-15 | Daly James M | Director | A-Award | A | Common Stock | 197 | 63.44 | 12.5K | 197 | D | ↗ |
| 2026-01-05 | Callos Andrew | Officer | M-Exempt | D | Non-Qualified Stock Option (Right to Buy) | 15,000 | 23.26 | 348.9K | 99,000 | D | ↗ |
| 2026-01-02 | Callos Andrew | Officer | M-Exempt | D | Incentive Stock Option (Right to Buy) | 885 | 37.63 | 33.3K | 1,772 | D | ↗ |
| 2025-12-29 | Callos Andrew | Officer | S-Sale | D | Common Stock | 1,809 | 62.44 | 113.0K | 51,353 | D | ↗ |
| 2025-12-22 | WIERENGA WENDELL | Director | S-Sale | D | Common Stock | 20,000 | 66.14 | 1.32M | 32,444 | D | ↗ |
| 2025-12-22 | Malik Fady Ibraham | Officer | A-Award | A | Common Stock | 2,000 | 0.00 | — | 140,552 | D | ↗ |
| 2025-12-22 | Lee Sung | Officer | F-InKind | D | Common Stock | 805 | 62.72 | 50.5K | 71,416 | D | ↗ |
| 2025-12-22 | Callos Andrew | Officer | A-Award | A | Common Stock | 1,589 | 0.00 | — | 52,249 | D | ↗ |
| 2025-12-22 | Blum Robert I | Director / Officer | M-Exempt | D | Incentive Stock Option (Right to Buy) | 16,506 | 6.67 | 110.1K | 0 | D | ↗ |
| 2025-12-16 | Malik Fady Ibraham | Officer | S-Sale | D | Common Stock | 2,200 | 61.24 | 134.7K | 138,552 | D | ↗ |
| 2025-12-08 | Callos Andrew | Officer | M-Exempt | A | Common Stock | 1,042 | 39.13 | 40.8K | 51,702 | D | ↗ |
| 2025-12-05 | Callos Andrew | Officer | M-Exempt | A | Common Stock | 15,000 | 23.26 | 348.9K | 65,660 | D | ↗ |
| 2025-12-03 | Malik Fady Ibraham | Officer | F-InKind | D | Common Stock | 2,058 | 65.02 | 133.8K | 138,552 | D | ↗ |
| 2025-12-03 | Lee Sung | Officer | F-InKind | D | Common Stock | 1,560 | 65.02 | 101.4K | 67,917 | D | ↗ |
| 2025-12-03 | Callos Andrew | Officer | F-InKind | D | Common Stock | 1,368 | 65.02 | 88.9K | 50,660 | D | ↗ |
| 2025-12-03 | Blum Robert I | Director / Officer | F-InKind | D | Common Stock | 5,930 | 65.02 | 385.6K | 350,202 | D | ↗ |
| 2025-12-02 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 2,200 | 10.60 | 23.3K | 142,810 | D | ↗ |
| 2025-12-02 | HENDERSON JOHN T | Director | M-Exempt | A | Common Stock | 8,750 | 10.00 | 87.5K | 83,328 | D | ↗ |
| 2025-12-01 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 28,064 | 66.72 | 1.87M | 9,977 | D | ↗ |
| 2025-12-01 | Harrington Robert Arthur | Director | S-Sale | D | Common Stock | 2,150 | 66.80 | 143.6K | 18,542 | D | ↗ |
| 2025-11-19 | PARSHALL B LYNNE | Director | S-Sale | D | Common Stock | 5,000 | 64.73 | 323.7K | 22,933 | D | ↗ |
| 2025-11-18 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 2,200 | 10.60 | 23.3K | 142,810 | D | ↗ |
| 2025-11-14 | Hessekiel Jeffrey | Officer | A-Award | A | Common Stock | 87,297 | 0.00 | — | 87,297 | D | ↗ |
| 2025-11-13 | Hessekiel Jeffrey | Officer | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-11-11 | Kaye Edward M. MD | Director | M-Exempt | A | Common Stock | 5,175 | 9.66 | 50.0K | 15,152 | D | ↗ |
| 2025-11-05 | Blum Robert I | Director / Officer | G-Gift | D | Common Stock | 2,000 | 0.00 | — | 356,108 | D | ↗ |
| 2025-11-04 | Malik Fady Ibraham | Officer | S-Sale | D | Common Stock | 2,295 | 59.55 | 136.7K | 140,610 | D | ↗ |
| 2025-10-30 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 5,000 | 62.86 | 314.3K | 358,108 | D | ↗ |
| 2025-10-27 | WIERENGA WENDELL | Director | M-Exempt | A | Common Stock | 4,375 | 10.00 | 43.8K | 36,819 | D | ↗ |
| 2025-10-21 | Malik Fady Ibraham | Officer | S-Sale | D | Common Stock | 2,105 | 58.22 | 122.6K | 140,610 | D | ↗ |
| 2025-10-16 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 5,000 | 60.03 | 300.2K | 363,108 | D | ↗ |
| 2025-10-15 | Wysenski Nancy | Director | A-Award | A | Common Stock | 99 | 62.80 | 6.2K | 30,873 | D | ↗ |
| 2025-10-15 | WIERENGA WENDELL | Director | A-Award | A | Common Stock | 99 | 62.80 | 6.2K | 32,444 | D | ↗ |
| 2025-10-15 | Kaye Edward M. MD | Director | A-Award | A | Common Stock | 199 | 62.80 | 12.5K | 9,977 | D | ↗ |
| 2025-10-15 | Harrington Robert Arthur | Director | A-Award | A | Common Stock | 199 | 62.80 | 12.5K | 20,692 | D | ↗ |
| 2025-10-15 | HENDERSON JOHN T | Director | A-Award | A | Common Stock | 338 | 62.80 | 21.2K | 74,578 | D | ↗ |
| 2025-10-07 | Malik Fady Ibraham | Officer | M-Exempt | D | Non-Qualified Stock Option (Right to Buy) | 2,000 | 10.60 | 21.2K | 3,105 | D | ↗ |
| 2025-10-06 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 6,757 | 60.00 | 405.4K | 9,778 | D | ↗ |
| 2025-10-01 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 5,000 | 55.05 | 275.3K | 368,108 | D | ↗ |
| 2025-09-30 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 6,695 | 55.08 | 368.8K | 16,535 | D | ↗ |
| 2025-09-23 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 2,000 | 10.60 | 21.2K | 142,610 | D | ↗ |
| 2025-09-15 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 5,000 | 49.77 | 248.9K | 373,108 | D | ↗ |
| 2025-09-09 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 2,000 | 10.60 | 21.2K | 142,610 | D | ↗ |
| 2025-09-02 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 6,756 | 50.00 | 337.8K | 23,230 | D | ↗ |
| 2025-09-02 | Harrington Robert Arthur | Director | S-Sale | D | Common Stock | 2,150 | 48.67 | 104.6K | 20,493 | D | ↗ |
| 2025-09-02 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 5,000 | 48.76 | 243.8K | 378,108 | D | ↗ |
| 2025-08-19 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 2,000 | 10.60 | 21.2K | 142,610 | D | ↗ |
| 2025-08-19 | Daly James M | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-15 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 5,000 | 38.42 | 192.1K | 383,108 | D | ↗ |
| 2025-08-05 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 2,000 | 10.60 | 21.2K | 142,610 | D | ↗ |
| 2025-07-29 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 5,000 | 36.45 | 182.3K | 388,108 | D | ↗ |
| 2025-07-22 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 2,000 | 10.60 | 21.2K | 142,610 | D | ↗ |
| 2025-07-15 | Wysenski Nancy | Director | A-Award | A | Common Stock | 164 | 38.01 | 6.2K | 30,774 | D | ↗ |
| 2025-07-15 | WIERENGA WENDALL | Director | A-Award | A | Common Stock | 164 | 38.01 | 6.2K | 32,345 | D | ↗ |
| 2025-07-15 | Kaye Edward M. MD | Director | A-Award | A | Common Stock | 328 | 38.01 | 12.5K | 29,986 | D | ↗ |
| 2025-07-15 | Harrington Robert Arthur | Director | A-Award | A | Common Stock | 328 | 38.01 | 12.5K | 22,643 | D | ↗ |
| 2025-07-15 | HENDERSON JOHN T | Director | A-Award | A | Common Stock | 559 | 38.01 | 21.2K | 74,240 | D | ↗ |
| 2025-07-14 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 5,000 | 38.15 | 190.8K | 393,108 | D | ↗ |
| 2025-07-08 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 2,000 | 10.60 | 21.2K | 142,610 | D | ↗ |
| 2025-07-01 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 5,000 | 33.55 | 167.8K | 398,108 | D | ↗ |
| 2025-06-17 | Malik Fady Ibraham | Officer | M-Exempt | D | Non-Qualified Stock Option (Right to Buy) | 2,000 | 10.60 | 21.2K | 17,105 | D | ↗ |
| 2025-06-16 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 5,000 | 33.80 | 169.0K | 403,108 | D | ↗ |
| 2025-06-05 | Kaye Edward M. MD | Director | S-Sale | D | Common Stock | 3,636 | 32.10 | 116.7K | 29,658 | D | ↗ |
| 2025-06-05 | Callos Andrew | Officer | S-Sale | D | Common Stock | 8,659 | 32.04 | 277.4K | 52,028 | D | ↗ |
| 2025-06-03 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 2,000 | 10.60 | 21.2K | 142,610 | D | ↗ |
| 2025-06-02 | Lee Sung | Officer | F-InKind | D | Common Stock | 4,965 | 31.21 | 155.0K | 69,477 | D | ↗ |
| 2025-06-02 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 5,000 | 31.22 | 156.1K | 408,108 | D | ↗ |
| 2025-05-20 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 2,000 | 10.60 | 21.2K | 142,255 | D | ↗ |
| 2025-05-16 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 5,000 | 30.93 | 154.7K | 412,629 | D | ↗ |
| 2025-05-15 | Bhanji Muna | Director | S-Sale | D | Common Stock | 1,454 | 29.73 | 43.2K | 23,510 | D | ↗ |
| 2025-05-14 | Wysenski Nancy | Director | A-Award | A | Common Stock | 7,333 | 0.00 | — | 30,610 | D | ↗ |
| 2025-05-14 | WIERENGA WENDALL | Director | A-Award | A | Common Stock | 7,333 | 0.00 | — | 32,181 | D | ↗ |
| 2025-05-14 | PARSHALL B LYNNE | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 10,880 | 30.00 | 326.4K | 10,880 | D | ↗ |
| 2025-05-14 | Landry Robert E | Director | A-Award | A | Common Stock | 7,333 | 0.00 | — | 7,333 | D | ↗ |
| 2025-05-14 | Kaye Edward M. MD | Director | A-Award | A | Common Stock | 7,333 | 0.00 | — | 33,294 | D | ↗ |
| 2025-05-14 | Harrington Robert Arthur | Director | A-Award | A | Common Stock | 7,333 | 0.00 | — | 22,315 | D | ↗ |
| 2025-05-14 | HENDERSON JOHN T | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 10,880 | 30.00 | 326.4K | 10,880 | D | ↗ |
| 2025-05-14 | Bhanji Muna | Director | A-Award | A | Common Stock | 7,333 | 0.00 | — | 24,964 | D | ↗ |
| 2025-05-06 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 2,000 | 10.60 | 21.2K | 142,255 | D | ↗ |
| 2025-05-05 | Callos Andrew | Officer | S-Sale | D | Common Stock | 4,002 | 36.68 | 146.8K | 60,687 | D | ↗ |
| 2025-04-29 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 5,000 | 40.96 | 204.8K | 417,629 | D | ↗ |
| 2025-04-22 | Malik Fady Ibraham | Officer | S-Sale | D | Common Stock | 2,000 | 38.11 | 76.2K | 140,255 | D | ↗ |
| 2025-04-21 | WIERENGA WENDALL | Director | M-Exempt | A | Common Stock | 20,000 | 6.21 | 124.2K | 44,848 | D | ↗ |
| 2025-04-15 | Wysenski Nancy | Director | A-Award | A | Common Stock | 162 | 38.56 | 6.2K | 23,277 | D | ↗ |
| 2025-04-15 | WIERENGA WENDALL | Director | A-Award | A | Common Stock | 162 | 38.56 | 6.2K | 24,848 | D | ↗ |
| 2025-04-15 | Kaye Edward M. MD | Director | A-Award | A | Common Stock | 324 | 38.56 | 12.5K | 25,961 | D | ↗ |
| 2025-04-15 | Harrington Robert Arthur | Director | A-Award | A | Common Stock | 324 | 38.56 | 12.5K | 14,982 | D | ↗ |
| 2025-04-15 | HENDERSON JOHN T | Director | A-Award | A | Common Stock | 551 | 38.56 | 21.2K | 66,348 | D | ↗ |
| 2025-04-10 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 5,000 | 36.77 | 183.9K | 422,629 | D | ↗ |
| 2025-04-08 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 2,000 | 10.60 | 21.2K | 142,255 | D | ↗ |
| 2025-04-07 | Callos Andrew | Officer | S-Sale | D | Common Stock | 2,886 | 35.78 | 103.3K | 64,689 | D | ↗ |
| 2025-04-03 | Harrington Robert Arthur | Director | S-Sale | D | Common Stock | 450 | 39.43 | 17.7K | 14,658 | D | ↗ |
| 2025-03-31 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 15,000 | 40.75 | 611.3K | 427,629 | D | ↗ |
| 2025-03-19 | Malik Fady Ibraham | Officer | G-Gift | D | Common Stock | 200 | 0.00 | — | 140,255 | D | ↗ |
| 2025-03-18 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 2,000 | 10.60 | 21.2K | 142,455 | D | ↗ |
| 2025-03-17 | Malik Fady Ibraham | Officer | S-Sale | D | Common Stock | 4,389 | 44.38 | 194.8K | 101,005 | D | ↗ |
| 2025-03-17 | Callos Andrew | Officer | S-Sale | D | Common Stock | 2,775 | 44.38 | 123.2K | 34,888 | D | ↗ |
| 2025-03-17 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 25,000 | 44.65 | 1.12M | 339,181 | D | ↗ |
| 2025-03-14 | Malik Fady Ibraham | Officer | A-Award | A | Common Stock | 39,450 | 0.00 | — | 144,844 | D | ↗ |
| 2025-03-14 | Lee Sung | Officer | A-Award | A | Common Stock | 32,687 | 0.00 | — | 74,442 | D | ↗ |
| 2025-03-14 | Callos Andrew | Officer | A-Award | A | Common Stock | 32,687 | 0.00 | — | 70,350 | D | ↗ |
| 2025-03-14 | Blum Robert I | Director / Officer | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 176,547 | 44.36 | 7.83M | 176,547 | D | ↗ |
| 2025-03-13 | Callos Andrew | Officer | S-Sale | D | Common Stock | 26,771 | 43.62 | 1.17M | 37,663 | D | ↗ |
| 2025-03-06 | Malik Fady Ibraham | Officer | S-Sale | D | Common Stock | 8,228 | 43.27 | 356.0K | 105,394 | D | ↗ |
| 2025-03-06 | Callos Andrew | Officer | S-Sale | D | Common Stock | 3,341 | 43.27 | 144.6K | 64,434 | D | ↗ |
| 2025-03-06 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 16,970 | 43.44 | 737.2K | 364,181 | D | ↗ |
| 2025-03-05 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 25,000 | 43.23 | 1.08M | 381,151 | D | ↗ |
| 2025-03-04 | Malik Fady Ibraham | Officer | S-Sale | D | Common Stock | 2,000 | 42.50 | 85.0K | 116,071 | D | ↗ |
| 2025-03-04 | Harrington Robert Arthur | Director | S-Sale | D | Common Stock | 900 | 42.50 | 38.3K | 15,108 | D | ↗ |
| 2025-03-03 | Malik Fady Ibraham | Officer | S-Sale | D | Common Stock | 2,449 | 42.88 | 105.0K | 113,622 | D | ↗ |
| 2025-03-03 | Callos Andrew | Officer | S-Sale | D | Common Stock | 1,114 | 42.88 | 47.8K | 67,775 | D | ↗ |
| 2025-03-03 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 8,743 | 42.88 | 374.9K | 406,151 | D | ↗ |
| 2025-02-18 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 2,000 | 10.60 | 21.2K | 118,071 | D | ↗ |
| 2025-02-10 | Landry Robert E | Director | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 25,538 | 42.21 | 1.08M | 25,538 | D | ↗ |
| 2025-02-04 | Malik Fady Ibraham | Officer | S-Sale | D | Common Stock | 2,000 | 48.06 | 96.1K | 116,071 | D | ↗ |
| 2025-01-21 | Malik Fady Ibraham | Officer | S-Sale | D | Common Stock | 2,000 | 45.92 | 91.8K | 116,071 | D | ↗ |
| 2025-01-07 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 2,000 | 10.60 | 21.2K | 118,071 | D | ↗ |
| 2025-01-02 | Wysenski Nancy | Director | A-Award | A | Common Stock | 127 | 48.93 | 6.2K | 23,115 | D | ↗ |
| 2025-01-02 | WIERENGA WENDALL | Director | A-Award | A | Common Stock | 127 | 48.93 | 6.2K | 24,686 | D | ↗ |
| 2025-01-02 | Kaye Edward M. MD | Director | A-Award | A | Common Stock | 255 | 48.93 | 12.5K | 25,637 | D | ↗ |
| 2025-01-02 | Harrington Robert Arthur | Director | A-Award | A | Common Stock | 255 | 48.93 | 12.5K | 16,008 | D | ↗ |
| 2025-01-02 | HENDERSON JOHN T | Director | A-Award | A | Common Stock | 434 | 48.93 | 21.2K | 48,987 | D | ↗ |
| 2024-12-16 | WIERENGA WENDALL | Director | M-Exempt | A | Common Stock | 742 | 7.37 | 5.5K | 25,301 | D | ↗ |
| 2024-12-11 | HENDERSON JOHN T | Director | S-Sale | D | Common Stock | 1,780 | 50.42 | 89.7K | 38,461 | D | ↗ |
| 2024-12-10 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 5,300 | 7.96 | 42.2K | 123,371 | D | ↗ |
| 2024-12-03 | Wong Robert | Officer | A-Award | A | Common Stock | 764 | 0.00 | — | 18,162 | D | ↗ |
| 2024-12-03 | Malik Fady Ibraham | Officer | A-Award | A | Common Stock | 4,000 | 0.00 | — | 116,099 | D | ↗ |
| 2024-12-03 | Lee Sung | Officer | F-InKind | D | Common Stock | 1,536 | 51.51 | 79.1K | 37,451 | D | ↗ |
| 2024-12-03 | Callos Andrew | Officer | F-InKind | D | Common Stock | 1,351 | 51.51 | 69.6K | 65,712 | D | ↗ |
| 2024-12-03 | Blum Robert I | Director / Officer | A-Award | A | Common Stock | 11,529 | 0.00 | — | 409,207 | D | ↗ |
| 2024-12-02 | Blum Robert I | Director / Officer | M-Exempt | A | Common Stock | 5,000 | 6.67 | 33.4K | 402,678 | D | ↗ |
| 2024-11-26 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 5,300 | 7.96 | 42.2K | 119,178 | D | ↗ |
| 2024-11-25 | WIERENGA WENDALL | Director | M-Exempt | A | Common Stock | 742 | 7.37 | 5.5K | 25,301 | D | ↗ |
| 2024-11-18 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 5,000 | 50.55 | 252.8K | 397,456 | D | ↗ |
| 2024-11-12 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 5,300 | 7.96 | 42.2K | 120,220 | D | ↗ |
| 2024-11-01 | Blum Robert I | Director / Officer | M-Exempt | A | Common Stock | 5,000 | 6.67 | 33.4K | 402,456 | D | ↗ |
| 2024-10-30 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 5,300 | 7.96 | 42.2K | 122,220 | D | ↗ |
| 2024-10-28 | WIERENGA WENDALL | Director | M-Exempt | D | Non-Qualified Stock Option (Right to Buy) | 4,452 | 7.37 | 32.8K | 1,484 | D | ↗ |
| 2024-10-15 | Malik Fady Ibraham | Officer | S-Sale | D | Common Stock | 5,300 | 54.18 | 287.2K | 118,920 | D | ↗ |
| 2024-10-09 | Blum Robert I | Director / Officer | M-Exempt | A | Common Stock | 5,000 | 6.67 | 33.4K | 402,456 | D | ↗ |
| 2024-10-01 | Wysenski Nancy | Director | A-Award | A | Common Stock | 118 | 52.60 | 6.2K | 22,988 | D | ↗ |
| 2024-10-01 | WIERENGA WENDALL | Director | A-Award | A | Common Stock | 118 | 52.60 | 6.2K | 24,559 | D | ↗ |
| 2024-10-01 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 5,300 | 7.96 | 42.2K | 124,220 | D | ↗ |
| 2024-10-01 | Kaye Edward M. MD | Director | A-Award | A | Common Stock | 237 | 52.60 | 12.5K | 25,382 | D | ↗ |
| 2024-10-01 | Harrington Robert Arthur | Director | A-Award | A | Common Stock | 237 | 52.60 | 12.5K | 15,753 | D | ↗ |
| 2024-10-01 | HENDERSON JOHN T | Director | A-Award | A | Common Stock | 403 | 52.60 | 21.2K | 38,461 | D | ↗ |
| 2024-09-30 | Blum Robert I | Director / Officer | M-Exempt | A | Common Stock | 5,000 | 6.67 | 33.4K | 402,456 | D | ↗ |
| 2024-09-17 | Malik Fady Ibraham | Officer | S-Sale | D | Common Stock | 2,000 | 56.76 | 113.5K | 120,920 | — | ↗ |
| 2024-09-16 | Blum Robert I | Director / Officer | M-Exempt | A | Common Stock | 5,000 | 6.67 | 33.4K | 402,456 | — | ↗ |
| 2024-09-09 | PARSHALL B LYNNE | Director | M-Exempt | A | Common Stock | 5,000 | 21.61 | 108.1K | 25,600 | — | ↗ |
| 2024-09-03 | Malik Fady Ibraham | Officer | M-Exempt | D | Non-Qualified Stock Option (Right to Buy) | 5,300 | 7.96 | 42.2K | 37,100 | — | ↗ |
| 2024-09-03 | Blum Robert I | Director / Officer | S-Sale | D | Common Stock | 5,000 | 57.03 | 285.2K | 397,456 | — | ↗ |
| 2024-08-30 | Pletcher Brett A | Officer | A-Award | A | Non-Qualified Stock Option (Right to Buy) | 51,039 | 57.08 | 2.91M | 51,039 | — | ↗ |
| 2024-08-26 | PARSHALL B LYNNE | Director | S-Sale | D | Common Stock | 5,000 | 57.26 | 286.3K | 20,600 | — | ↗ |
| 2024-08-20 | Malik Fady Ibraham | Officer | M-Exempt | A | Common Stock | 5,300 | 7.96 | 42.2K | 130,304 | — | ↗ |
| 2024-08-19 | Blum Robert I | Director / Officer | G-Gift | D | Common Stock | 1,956 | 0.00 | — | 397,456 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-11.7K
Shares Outstanding
123.16M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Robert I. Blum, Principal Executive Officer | 853.1K | — | 5.15M | 5.10M | 772.7K | 9.7K | 11.88M | 86.23% | ↗ |
| 2 | 2025 | Jeffrey Hessekiel, Executive Vice President, Chief Legal & Administrative Officer | 85.3K | 200.0K | 5.80M | — | — | 954.00 | 6.09M | 95.30% | ↗ |
| 3 | 2025 | Fady I. Malik, Executive Vice President, Research and Development | 629.8K | — | 1.75M | 1.73M | 335.1K | 20.5K | 4.47M | 77.94% | ↗ |
| 4 | 2025 | Andrew M. Callos, Executive Vice President, Chief Commercial Officer | 581.7K | — | 1.45M | 1.43M | 303.0K | 18.2K | 3.79M | 76.16% | ↗ |
| 5 | 2025 | Sung H. Lee, Principal Financial Officer | 572.9K | — | 1.45M | 1.43M | 295.6K | 17.5K | 3.77M | 76.50% | ↗ |
| 6 | 2024 | Robert I. Blum, Principal Executive Officer | 819.6K | — | 9.80M | 3.06M | 681.1K | 2.7K | 14.36M | 89.53% | ↗ |
| 7 | 2024 | Sung H. Lee, Principal Financial Officer | 356.3K | 80.0K | 3.35M | 1.75M | 177.5K | 7.1K | 5.73M | 89.16% | ↗ |
| 8 | 2024 | Brett Pletcher, Former Executive Vice President and Chief Legal Officer | 560.0K | 100.0K | 2.69M | 1.97M | 99.0K | — | 5.42M | 86.00% | ↗ |
| 9 | 2024 | Fady I. Malik, Executive Vice President, Research and Development | 605.6K | — | 3.40M | 1.06M | 288.0K | 13.4K | 5.37M | 83.11% | ↗ |
| 10 | 2024 | Andrew M. Callos, Executive Vice President, Chief Commercial Officer | 556.4K | — | 2.70M | 843.1K | 269.1K | 14.9K | 4.38M | 80.83% | ↗ |
| 11 | 2024 | Ching W. Jaw, Former Principal Financial Officer | 78.9K | — | 1.08M | 495.0K | — | 20.3K | 1.68M | 94.09% | ↗ |
| 12 | 2023 | Robert I. Blum, Principal Executive Officer | 790.0K | — | 3.23M | 4.20M | 533.3K | 2.8K | 8.75M | 84.85% | ↗ |
| 13 | 2023 | Robert I. Blum, Principal Executive Officer | 782.1K | — | 3.23M | 4.20M | 533.3K | 2.8K | 8.74M | 84.92% | ↗ |
| 14 | 2023 | Fady I. Malik, Executive Vice President, Research and Development | 586.0K | — | 1.57M | 2.03M | 240.6K | 13.0K | 4.44M | 81.09% | ↗ |
| 15 | 2023 | Fady I. Malik, Executive Vice President, Research and Development | 581.4K | — | 1.57M | 2.03M | 240.6K | 13.0K | 4.44M | 81.17% | ↗ |
| 16 | 2023 | Andrew M. Callos, Executive Vice President, Chief Commercial Officer | 523.6K | — | 1.17M | 1.27M | 220.9K | 8.3K | 3.20M | 76.46% | ↗ |
| 17 | 2023 | Andrew M. Callos, Executive Vice President, Chief Commercial Officer | 518.7K | — | 1.17M | 1.27M | 220.9K | 8.3K | 3.19M | 76.58% | ↗ |
| 18 | 2023 | Ching W. Jaw, Former Principal Financial Officer | 526.0K | — | 1.17M | 1.27M | — | 11.4K | 2.98M | 81.99% | ↗ |
| 19 | 2023 | Ching W. Jaw, Former Principal Financial Officer | 526.0K | — | 1.17M | 1.27M | — | 11.4K | 2.98M | 81.99% | ↗ |
| 20 | 2023 | Robert C. Wong, Vice President, Chief Accounting Officer | 379.6K | — | 234.8K | 305.2K | 103.6K | 12.5K | 1.04M | 52.14% | ↗ |
| 21 | 2022 | Robert I. Blum, Principal Executive Officer | 742.4K | — | 3.20M | 4.21M | 395.7K | 960.00 | 8.55M | 86.67% | ↗ |
| 22 | 2022 | Robert I. Blum, Principal Executive Officer | 742.4K | — | 3.20M | 4.21M | 395.7K | 960.00 | 8.55M | 86.67% | ↗ |
| 23 | 2022 | Mr. Blum, Principal Executive Officer | 742.4K | — | 3.20M | 4.21M | 395.7K | 960.00 | 8.55M | 86.67% | ↗ |
| 24 | 2022 | Fady I. Malik, Executive Vice President, Research and Development | 558.1K | — | 1.13M | 1.64M | 207.8K | 11.0K | 3.54M | 78.07% | ↗ |
| 25 | 2022 | Fady I. Malik, Executive Vice President, Research and Development | 558.1K | — | 1.13M | 1.64M | 207.8K | 11.0K | 3.54M | 78.07% | ↗ |
| 26 | 2022 | Dr. Malik, Executive Vice President, Research and Development | 558.1K | — | 1.13M | 1.64M | 207.8K | 11.0K | 3.54M | 78.07% | ↗ |
| 27 | 2022 | Ching W. Jaw, Former Principal Financial Officer | 496.2K | — | 752.6K | 1.17M | 193.1K | 9.2K | 2.62M | 73.35% | ↗ |
| 28 | 2022 | Mr. Jaw, Principal Financial Officer | 496.2K | — | 752.6K | 1.17M | 193.1K | 9.2K | 2.62M | 73.35% | ↗ |
| 29 | 2022 | Ching W. Jaw, Former Principal Financial Officer | 496.2K | — | 752.6K | 1.17M | 193.1K | 9.2K | 2.62M | 73.35% | ↗ |
| 30 | 2022 | Andrew M. Callos, Executive Vice President, Chief Commercial Officer | 494.0K | — | 752.6K | 1.05M | 189.5K | 61.9K | 2.55M | 70.77% | ↗ |
| 31 | 2022 | Andrew M. Callos, Executive Vice President, Chief Commercial Officer | 494.0K | — | 752.6K | 1.05M | 189.5K | 61.9K | 2.55M | 70.77% | ↗ |
| 32 | 2022 | Mr. Callos, Executive Vice President, Chief Commercial Officer | 494.0K | — | 752.6K | 1.05M | 189.5K | 61.9K | 2.55M | 70.77% | ↗ |
| 33 | 2022 | Mr. Cragg, Senior Vice President, Chief Human Resources and Administration Officer | 222.8K | — | 752.6K | 1.17M | — | 29.8K | 2.17M | 88.39% | ↗ |
| 34 | 2022 | Mr. Schlossberg, Senior Vice President, Legal and General Counsel and Secretary | 186.6K | — | 752.6K | 1.05M | — | — | 1.99M | 90.63% | ↗ |
| 35 | 2022 | Mr. Wong, Vice President, Chief Accounting Officer | 361.5K | — | 282.2K | 327.5K | 91.4K | 10.9K | 1.07M | 56.80% | ↗ |
| 36 | 2022 | Robert C. Wong, Vice President, Chief Accounting Officer | 361.5K | — | 282.2K | 327.5K | 91.4K | 10.9K | 1.07M | 56.80% | ↗ |
| 37 | 2021 | Mr. Blum, Principal Executive Officer | 709.3K | — | 3.32M | 1.96M | 428.3K | 805.00 | 6.41M | 82.25% | ↗ |
| 38 | 2021 | Robert I. Blum, Principal Executive Officer | 709.3K | — | 3.32M | 1.96M | 428.3K | 805.00 | 6.41M | 82.25% | ↗ |
| 39 | 2021 | Mr. Callos, Executive Vice President, Chief Commercial Officer | 376.0K | — | 630.8K | 2.13M | 149.3K | 35.8K | 3.32M | 83.11% | ↗ |
| 40 | 2021 | Andrew M. Callos, Executive Vice President, Chief Commercial Officer | 376.0K | — | 630.8K | 2.13M | 149.3K | 35.8K | 3.32M | 83.11% | ↗ |
| 41 | 2021 | Fady I. Malik, Executive Vice President, Research and Development | 533.2K | — | 1.56M | 711.6K | 209.8K | 10.5K | 3.03M | 75.11% | ↗ |
| 42 | 2021 | Dr. Malik, Executive Vice President, Research and Development | 533.2K | — | 1.56M | 711.6K | 209.8K | 10.5K | 3.03M | 75.11% | ↗ |
| 43 | 2021 | Mr. Schlossberg, Senior Vice President, Legal and General Counsel and Secretary | 483.6K | — | 1.12M | 533.7K | 185.0K | 8.7K | 2.33M | 70.90% | ↗ |
| 44 | 2021 | Mr. Jaw, Principal Financial Officer | 472.6K | — | 1.12M | 533.7K | 188.9K | 8.7K | 2.32M | 71.11% | ↗ |
| 45 | 2021 | Ching W. Jaw, Former Principal Financial Officer | 472.6K | — | 1.12M | 533.7K | 188.9K | 8.7K | 2.32M | 71.11% | ↗ |
| 46 | 2021 | Mr. Cragg, Senior Vice President, Chief Human Resources and Administration Officer | 412.2K | — | 1.12M | 533.7K | 161.8K | 8.7K | 2.23M | 73.90% | ↗ |
| 47 | 2020 | Mr. Blum, Principal Executive Officer | 682.0K | — | 1.73M | 2.35M | 370.7K | 840.00 | 5.13M | 79.46% | ↗ |
| 48 | 2020 | Dr. Malik, Executive Vice President, Research and Development | 512.7K | — | 720.0K | 880.2K | 189.4K | 10.2K | 2.31M | 69.20% | ↗ |
| 49 | 2020 | Mr. Cragg, Chief Human Resources and Administration Officer | 396.4K | — | 432.0K | 864.0K | 135.4K | 9.3K | 1.84M | 70.55% | ↗ |
| 50 | 2020 | Mr. Schlossberg, Senior Vice President, Legal and General Counsel and Secretary | 465.0K | — | 432.0K | 586.8K | 170.8K | 9.3K | 1.66M | 61.23% | ↗ |
| 51 | 2020 | Mr. Jaw, Principal Financial Officer | 447.2K | — | 432.0K | 586.8K | 164.3K | 9.3K | 1.64M | 62.14% | ↗ |
| 52 | 2020 | Mr. Cragg, Senior Vice President, Chief Human Resources and Administration Officer | 396.4K | — | 432.0K | 586.8K | 145.6K | 9.3K | 1.57M | 64.89% | ↗ |
| 53 | 2019 | Mr. Blum, Principal Executive Officer | 655.6K | 250.0K | 856.8K | 1.71M | — | — | 3.48M | 73.95% | ↗ |
| 54 | 2019 | Dr. Malik, Executive Vice President, Research and Development | 493.0K | 150.3K | 357.0K | 571.2K | — | 9.2K | 1.58M | 58.72% | ↗ |
| 55 | 2019 | Mr. Schlossberg, Senior Vice President, Legal and General Counsel and Secretary | 434.7K | — | — | 703.0K | — | 129.8K | 1.27M | 55.46% | ↗ |
| 56 | 2019 | Mr. Jaw, Principal Financial Officer | 430.0K | 110.0K | 214.2K | 357.0K | — | 9.2K | 1.12M | 50.98% | ↗ |
| 57 | 2019 | Mr. Cragg, Chief Human Resources and Administration Officer | 375.8K | 95.7K | 214.2K | 357.0K | — | 9.2K | 1.05M | 54.31% | ↗ |
| 58 | 2018 | Mr. Blum, Principal Executive Officer | 630.4K | 295.2K | 780.0K | 1.56M | — | — | 3.27M | 71.66% | ↗ |
| 59 | 2018 | Dr. Malik, Executive Vice President, Research and Development | 474.8K | 150.5K | 312.0K | 585.0K | — | 8.7K | 1.53M | 58.59% | ↗ |
| 60 | 2018 | Mr. Cragg, Chief Human Resources and Administration Officer | 333.3K | 91.7K | 234.0K | 312.0K | — | 9.0K | 980.0K | 55.71% | ↗ |
| 61 | 2018 | Mr. Jaw, Principal Financial Officer | 415.1K | 67.7K | 156.0K | 312.0K | — | 3.2K | 954.0K | 49.06% | ↗ |
| 62 | 2017 | Mr. Blum, Principal Executive Officer | 611.7K | 350.0K | 431.6K | 1.47M | — | — | 2.87M | 66.47% | ↗ |
| 63 | 2017 | Dr. Malik, Executive Vice President, Research and Development | 460.9K | 175.0K | 215.8K | 359.7K | — | 8.6K | 1.22M | 47.17% | ↗ |
| 64 | 2017 | Dr. Malik, Named Executive Officer | 460.9K | 175.0K | 215.8K | 359.7K | — | 8.6K | 1.22M | 47.17% | ↗ |
| 65 | 2017 | Mr. Jaw, Principal Financial Officer | 212.9K | — | — | 611.1K | — | 150.9K | 974.9K | 62.69% | ↗ |
| 66 | 2017 | Mr. Cragg, Chief Human Resources and Administration Officer | 315.9K | 101.1K | 212.0K | 212.0K | — | 5.2K | 846.2K | 50.11% | ↗ |
| 67 | 2017 | Dr. Morgan, Named Executive Officer | 340.5K | 120.0K | 143.9K | 143.9K | — | 8.1K | 756.4K | 38.04% | ↗ |
| 68 | 2017 | Dr. Wolff, Named Executive Officer | 402.4K | 110.0K | 107.9K | 107.9K | — | — | 728.1K | 29.64% | ↗ |
| 69 | 2017 | Ms. Barbari, Former Principal Financial Officer | 254.3K | — | — | — | — | 14.0K | 268.4K | 0.00% | ↗ |
| 70 | 2016 | Mr. Blum, Principal Executive Officer | 591.7K | 350.0K | — | 1.24M | — | — | 2.18M | 56.76% | ↗ |
| 71 | 2016 | Robert I. Blum President and Chief Executive Officer | 591.7K | 350.0K | — | 1.24M | — | — | 2.18M | 56.76% | ↗ |
| 72 | 2016 | Dr. Malik, Named Executive Officer | 447.9K | 170.9K | — | 449.6K | — | 8.0K | 1.08M | 41.77% | ↗ |
| 73 | 2016 | Dr. Malik, Executive Vice President, Research and Development | 447.9K | 170.9K | — | 449.6K | — | 8.0K | 1.08M | 41.77% | ↗ |
| 74 | 2016 | Fady Malik, M.D., Ph.D. Executive Vice President, Research and Development | 447.9K | 170.9K | — | 449.6K | — | 8.0K | 1.08M | 41.77% | ↗ |
| 75 | 2016 | Ms. Barbari, Former Principal Financial Officer | 411.1K | 156.9K | — | 404.6K | — | 8.0K | 980.5K | 41.26% | ↗ |
| 76 | 2016 | Sharon A. Barbari Executive Vice President, Finance and Chief Financial Officer | 411.1K | 156.9K | — | 404.6K | — | 8.0K | 980.5K | 41.26% | ↗ |
| 77 | 2016 | Dr. Wolff, Named Executive Officer | 394.5K | 100.0K | — | 179.8K | — | — | 674.3K | 26.67% | ↗ |
| 78 | 2016 | Andrew Wolff, M.D. Senior Vice President, Chief Medical Officer | 394.5K | 100.0K | — | 179.8K | — | — | 674.3K | 26.67% | ↗ |
| 79 | 2016 | Bradley P. Morgan, Ph.D. Senior Vice President, Research and Non-Clinical Development | 330.6K | 110.5K | — | 224.8K | — | 8.0K | 673.8K | 33.36% | ↗ |
| 80 | 2016 | Dr. Morgan, Named Executive Officer | 330.6K | 110.5K | — | 224.8K | — | 8.0K | 673.8K | 33.36% | ↗ |
| 81 | 2016 | Mr. Cragg, Chief Human Resources and Administration Officer | 306.0K | 92.9K | — | 247.3K | — | 8.8K | 655.0K | 37.75% | ↗ |
| 82 | 2015 | Robert I. Blum President and Chief Executive Officer | 571.7K | 310.5K | 1.26M | 1.12M | — | — | 3.26M | 72.98% | ↗ |
| 83 | 2015 | Mr. Blum, Principal Executive Officer | 571.7K | 310.5K | 1.26M | 1.12M | — | — | 3.26M | 72.98% | ↗ |
| 84 | 2015 | Fady Malik, M.D., Ph.D. Executive Vice President, Research and Development | 415.9K | 157.9K | 699.9K | 561.2K | — | 8.0K | 1.84M | 68.43% | ↗ |
| 85 | 2015 | Dr. Malik, Named Executive Officer | 415.9K | 157.9K | 699.9K | 561.2K | — | 8.0K | 1.84M | 68.43% | ↗ |
| 86 | 2015 | Ms. Barbari, Former Principal Financial Officer | 402.7K | 145.0K | 524.9K | 420.9K | — | 8.0K | 1.50M | 62.99% | ↗ |
| 87 | 2015 | Sharon A. Barbari Executive Vice President, Finance and Chief Financial Officer | 402.7K | 145.0K | 524.9K | 420.9K | — | 8.0K | 1.50M | 62.99% | ↗ |
| 88 | 2015 | Bonnie A. Charpentier, Ph.D. Senior Vice President, Regulatory Affairs and Compliance | 307.5K | 96.0K | 419.9K | 224.5K | — | 8.0K | 1.06M | 61.03% | ↗ |
| 89 | 2015 | David W. Cragg Senior Vice President, Human Resources | 293.5K | 92.9K | 419.9K | 224.5K | — | 8.0K | 1.04M | 62.04% | ↗ |
| 90 | 2015 | Andrew Wolff, M.D. Senior Vice President, Chief Medical Officer | 388.0K | 90.0K | 350.0K | 196.4K | — | — | 1.02M | 53.34% | ↗ |
| 91 | 2015 | Dr. Wolff, Named Executive Officer | 388.0K | 90.0K | 350.0K | 196.4K | — | — | 1.02M | 53.34% | ↗ |
| 92 | 2015 | Bradley P. Morgan, Ph.D. Senior Vice President, Research and Non-Clinical Development | 307.1K | 88.8K | 419.9K | 168.4K | — | 8.0K | 992.2K | 59.29% | ↗ |
| 93 | 2015 | Dr. Morgan, Named Executive Officer | 307.1K | 88.8K | 419.9K | 168.4K | — | 8.0K | 992.2K | 59.29% | ↗ |
| 94 | 2014 | Robert I. Blum President and Chief Executive Officer | 555.0K | 323.0K | — | 1.31M | — | — | 2.19M | 59.89% | ↗ |
| 95 | 2014 | Robert I. Blum President and Chief Executive Officer | 555.0K | — | — | 1.31M | 323.0K | — | 2.19M | 59.89% | ↗ |
| 96 | 2014 | Fady Malik, M.D., Ph.D. Executive Vice President, Research and Development | 384.6K | 131.9K | — | 655.5K | — | 7.8K | 1.18M | 55.56% | ↗ |
| 97 | 2014 | Fady Malik, M.D., Ph.D. Senior Vice President, Research and Development | 384.6K | — | — | 655.5K | 131.9K | 7.8K | 1.18M | 55.56% | ↗ |
| 98 | 2014 | Sharon A. Barbari Executive Vice President, Finance and Chief Financial Officer | 400.8K | 446.00 | — | 458.8K | 153.4K | 7.8K | 1.02M | 44.93% | ↗ |
| 99 | 2014 | Sharon A. Barbari Executive Vice President, Finance and Chief Financial Officer | 400.8K | 153.9K | — | 458.8K | — | 7.8K | 1.02M | 44.93% | ↗ |
| 100 | 2014 | David W. Cragg Senior Vice President, Human Resources | 285.0K | 95.5K | — | 295.0K | — | 7.8K | 683.2K | 43.17% | ↗ |
| 101 | 2014 | David W. Cragg Senior Vice President, Human Resources | 285.0K | — | — | 295.0K | 95.5K | 7.8K | 683.2K | 43.17% | ↗ |
| 102 | 2014 | Bonnie A. Charpentier, Ph.D. Senior Vice President, Regulatory Affairs and Compliance | 300.0K | 100.0K | — | 157.7K | — | 7.8K | 565.5K | 27.89% | ↗ |
| 103 | 2014 | Andrew Wolff, M.D. Senior Vice President, Chief Medical Officer | 388.0K | 85.0K | — | — | — | — | 473.0K | 0.00% | ↗ |
| 104 | 2013 | Robert I. Blum President and Chief Executive Officer | 555.0K | 249.8K | — | 518.0K | — | — | 1.32M | 39.16% | ↗ |
| 105 | 2013 | Robert I. Blum President and Chief Executive Officer | 555.0K | — | — | 518.0K | 249.8K | — | 1.32M | 39.16% | ↗ |
| 106 | 2013 | Sharon A. Barbari Executive Vice President, Finance and Chief Financial Officer | 391.0K | 140.8K | — | 194.3K | — | — | 726.0K | 26.76% | ↗ |
| 107 | 2013 | Sharon A. Barbari Executive Vice President, Finance and Chief Financial Officer | 391.0K | — | — | 194.3K | 140.8K | — | 726.0K | 26.76% | ↗ |
| 108 | 2013 | Andrew A. Wolff, M.D., F.A.C.C. Senior Vice President, Clinical Research and Development and Chief Medical Officer | 388.0K | — | — | 161.9K | 108.6K | — | 658.5K | 24.58% | ↗ |
| 109 | 2013 | Fady Malik, M.D., Ph.D. Executive Vice President, Research and Development | 347.5K | 98.5K | — | 194.3K | — | — | 640.3K | 30.34% | ↗ |
| 110 | 2013 | Fady Malik, M.D., Ph.D. Senior Vice President, Research and Development | 347.5K | — | — | 194.3K | 98.5K | — | 640.3K | 30.34% | ↗ |
| 111 | 2013 | Fady Malik, M.D., Ph.D. Senior Vice President, Research and Early Development | 347.5K | — | — | 194.3K | 98.5K | — | 640.3K | 30.34% | ↗ |
| 112 | 2013 | David W. Cragg Senior Vice President, Human Resources | 278.0K | — | — | 97.1K | 75.1K | — | 450.2K | 21.57% | ↗ |
| 113 | 2013 | David W. Cragg Senior Vice President, Human Resources | 278.0K | 75.1K | — | 97.1K | — | — | 450.2K | 21.57% | ↗ |
| 114 | 2012 | Robert I. Blum President and Chief Executive Officer | 555.0K | — | — | 299.2K | 242.8K | — | 1.10M | 27.27% | ↗ |
| 115 | 2012 | Sharon A. Barbari Executive Vice President, Finance and Chief Financial Officer | 391.0K | — | — | 116.4K | 139.8K | — | 647.1K | 17.98% | ↗ |
| 116 | 2012 | Andrew A. Wolff, M.D., F.A.C.C. Senior Vice President, Clinical Research and Development and Chief Medical Officer | 388.0K | — | — | 116.4K | 118.0K | — | 622.3K | 18.70% | ↗ |
| 117 | 2012 | Fady Malik, M.D., Ph.D. Senior Vice President, Research and Development | 310.0K | — | — | 116.4K | 83.1K | — | 509.5K | 22.84% | ↗ |
| 118 | 2012 | Fady Malik, M.D., Ph.D. Senior Vice President, Research and Early Development | 310.0K | — | — | 116.4K | 83.1K | — | 509.5K | 22.84% | ↗ |
| 119 | 2012 | Fady Malik, M.D., Ph.D.. | 310.0K | — | 116.4K | — | 83.1K | — | 509.5K | 22.84% | ↗ |
| 120 | 2012 | David W. Cragg Senior Vice President, Human Resources | 278.0K | — | — | 59.8K | 73.5K | — | 411.3K | 14.55% | ↗ |
| 121 | 2011 | Robert I. Blum President and Chief Executive Officer | 550.0K | — | 395.2K | 513.1K | — | — | 1.46M | 62.28% | ↗ |
| 122 | 2011 | David J. Morgans, Jr., Ph.D. Former Executive Vice President, Preclinical Research and Development | 343.6K | — | — | 179.6K | — | 419.0K | 942.2K | 19.06% | ↗ |
| 123 | 2011 | Sharon A. Barbari Executive Vice President, Finance and Chief Financial Officer | 389.7K | — | 225.8K | 205.2K | — | — | 820.7K | 52.52% | ↗ |
| 124 | 2011 | Andrew A. Wolff, M.D., F.A.C.C Senior Vice President, Clinical Research and Development and Chief Medical Officer | 386.4K | — | 197.6K | 205.2K | — | — | 789.2K | 51.04% | ↗ |
| 125 | 2011 | Andrew A. Wolff, M.D., F.A.C.C. Senior Vice President, Clinical Research and Development and Chief Medical Officer | 386.4K | — | 197.6K | 205.2K | — | — | 789.2K | 51.04% | ↗ |
| 126 | 2011 | Fady Malik, M.D., Ph.D. Senior Vice President, Research and Early Development | 282.6K | — | 197.6K | 77.0K | 38.7K | — | 595.8K | 46.08% | ↗ |
| 127 | 2011 | David W. Cragg Senior Vice President, Human Resources | 277.1K | — | 141.1K | 102.6K | — | — | 520.8K | 46.80% | ↗ |
| 128 | 2010 | Robert I. Blum President and Chief Executive Officer | 520.8K | — | — | 552.7K | 183.8K | — | 1.26M | 43.96% | ↗ |
| 129 | 2010 | Sharon A. Barbari Executive Vice President, Finance and Chief Financial Officer | 381.2K | — | — | 276.3K | 114.9K | — | 772.4K | 35.78% | ↗ |
| 130 | 2010 | David J. Morgans, Jr., Ph.D. Former Executive Vice President, Preclinical Research and Development | 376.8K | — | — | 276.3K | 106.3K | 9.9K | 769.3K | 35.92% | ↗ |
| 131 | 2010 | Andrew A. Wolff, M.D., F.A.C.C. Senior Vice President, Clinical Research and Development and Chief Medical Officer | 376.9K | — | — | 276.3K | 85.1K | — | 738.3K | 37.43% | ↗ |
| 132 | 2010 | Andrew A. Wolff, M.D., F.A.C.C Senior Vice President, Clinical Research and Development and Chief Medical Officer | 376.9K | — | — | 276.3K | 85.1K | — | 738.3K | 37.43% | ↗ |
| 133 | 2010 | David W. Cragg Senior Vice President, Human Resources | 271.3K | — | — | 184.2K | 59.3K | — | 514.7K | 35.79% | ↗ |
| 134 | 2009 | Robert I. Blum President and Chief Executive Officer | 470.0K | 190.0K | — | 345.4K | 225.0K | — | 1.23M | 28.07% | ↗ |
| 135 | 2009 | David J. Morgans, Jr., Ph.D. Executive Vice President, Preclinical Research and Development | 357.5K | 130.0K | — | — | 127.1K | 10.4K | 813.4K | 0.00% | ↗ |
| 136 | 2009 | David J. Morgans, Jr., Ph.D. Former Executive Vice President, Preclinical Research and Development | 357.5K | 130.0K | — | 188.4K | 127.1K | 10.4K | 813.4K | 23.16% | ↗ |
| 137 | 2009 | Sharon A. Barbari Executive Vice President, Finance and Chief Financial Officer | 359.8K | 100.0K | — | 188.4K | 133.9K | — | 782.1K | 24.09% | ↗ |
| 138 | 2009 | Andrew A. Wolff, M.D., F.A.C.C Senior Vice President, Clinical Research and Development and Chief Medical Officer | 365.0K | 100.0K | — | 163.3K | 97.1K | — | 725.4K | 22.51% | ↗ |
| 139 | 2009 | Michael S. Rabson, Ph.D. Senior Vice President, Business Development Legal Affairs and General Counsel | 355.0K | 75.0K | — | — | — | — | 568.1K | 0.00% | ↗ |
| 140 | 2008 | Robert I. Blum President and Chief Executive Officer | 433.3K | 3.6K | — | — | — | — | 841.6K | 0.00% | ↗ |
| 141 | 2008 | David J. Morgans, Jr., Ph.D. Executive Vice President, Preclinical Research and Development | 346.7K | 3.0K | — | — | — | 50.7K | 703.9K | 0.00% | ↗ |
| 142 | 2008 | Andrew A. Wolff, M.D., F.A.C.C Senior Vice President, Clinical Research and Development and Chief Medical Officer | 346.7K | 3.0K | — | — | — | 50.7K | 703.9K | 0.00% | ↗ |
| 143 | 2008 | Michael S. Rabson, Ph.D. Senior Vice President, Business Development Legal Affairs and General Counsel | 263.8K | — | — | — | — | — | 661.5K | 0.00% | ↗ |
| 144 | 2008 | Sharon A. Barbari Executive Vice President, Finance and Chief Financial Officer | 345.3K | — | — | — | — | — | 598.2K | 0.00% | ↗ |
| 145 | 2008 | Jay K. Trautman, Ph.D. Vice President, Discovery Research and Technology | — | — | — | — | — | — | — | — | ↗ |
| 146 | 2008 | Sharon A. Barbari Senior Vice President, Finance and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 147 | 2007 | Robert I. Blum President and Chief Executive Officer | 397.8K | 36.5K | — | — | 90.0K | — | 1.68M | 0.00% | ↗ |
| 148 | 2007 | James H. Sabry, M.D., Ph.D. Executive Chairman of the Board of Directors | 435.0K | — | — | — | 100.1K | 58.0K | 1.11M | 0.00% | ↗ |
| 149 | 2007 | David J. Morgans, Jr., Ph.D. Executive Vice President, Preclinical Research and Development | 316.7K | 30.2K | — | — | 58.8K | 53.5K | 758.9K | 0.00% | ↗ |
| 150 | 2007 | Andrew Wolff, M.D., F.A.C.C Senior Vice President, Clinical Research and Development and Chief Medical Officer | 349.2K | — | — | — | 47.4K | — | 725.7K | 0.00% | ↗ |
| 151 | 2007 | Sharon A. Barbari Executive Vice President, Finance and Chief Financial Officer | 331.7K | — | — | — | 56.4K | — | 664.7K | 0.00% | ↗ |
| 152 | 2007 | Andrew A. Wolff, M.D., F.A.C.C Senior Vice President, Clinical Research and Development and Chief Medical Officer | 349.2K | — | — | — | 47.4K | — | 650.1K | 0.00% | ↗ |
| 153 | 2007 | Sharon A. Barbari Senior Vice President, Finance and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 154 | 2007 | Jay K. Trautman, Ph.D. Vice President, Discovery Research and Technology | — | — | — | — | — | — | — | — | ↗ |
| 155 | 2007 | Michael S. Rabson, Ph.D. Senior Vice President, Business Development Legal Affairs and General Counsel | — | — | — | — | — | — | — | — | ↗ |
| 156 | 2006 | James H. Sabry, M.D., Ph.D. Executive Chairman of the Board of Directors | 431.7K | — | — | — | 143.6K | 60.6K | 1.12M | 0.00% | ↗ |
| 157 | 2006 | Andrew Wolff, M.D., F.A.C.C Senior Vice President, Clinical Research and Development and Chief Medical Officer | 338.3K | — | — | — | 64.5K | — | 665.5K | 0.00% | ↗ |
| 158 | 2006 | Sharon A. Barbari Senior Vice President, Finance and Chief Financial Officer | — | — | — | — | — | — | — | — | ↗ |
| 159 | 2006 | Michael S. Rabson, Ph.D. Senior Vice President, Business Development Legal Affairs and General Counsel | — | — | — | — | — | — | — | — | ↗ |
| 160 | 2006 | David J. Morgans, Jr., Ph.D. Executive Vice President, Preclinical Research and Development | — | — | — | — | — | — | — | — | ↗ |
| 161 | 2006 | Robert I. Blum President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 162 | 2006 | Jay K. Trautman, Ph.D. Vice President, Discovery Research and Technology | — | — | — | — | — | — | — | — | ↗ |
| 163 | 2006 | Andrew A. Wolff, M.D., F.A.C.C Senior Vice President, Clinical Research and Development and Chief Medical Officer | — | — | — | — | — | — | — | — | ↗ |
| 164 | 2006 | Andrew Wolff, M.D., F.A.C.C. | — | — | — | — | — | — | — | — | ↗ |
| 165 | 2006 | Sharon A. Surrey-Barbari | — | — | — | — | — | — | — | — | ↗ |
| 166 | 2006 | David J. Morgans, Jr., Ph.D. | — | — | — | — | — | — | — | — | ↗ |
| 167 | 2006 | Robert I. Blum | — | — | — | — | — | — | — | — | ↗ |
| 168 | 2006 | James H. Sabry, M.D., Ph.D. | — | — | — | — | — | — | — | — | ↗ |
| 169 | 2005 | James H. Sabry, M.D., Ph.D. Chief Executive Officer | 412.5K | 132.8K | — | — | — | 1.2K | 546.5K | 0.00% | ↗ |
| 170 | 2005 | Robert I. Blum President | 329.2K | 140.1K | — | — | — | 687.00 | 469.9K | 0.00% | ↗ |
| 171 | 2005 | Andrew Wolff, M.D., F.A.C.C. Senior Vice President, Clinical | 329.2K | 66.0K | — | — | — | 1.6K | 396.8K | 0.00% | ↗ |
| 172 | 2005 | Sharon A. Surrey-Barbari Senior Vice President, Finance | 309.2K | 65.9K | — | — | — | 1.5K | 376.6K | 0.00% | ↗ |
| 173 | 2005 | David J. Morgans, Jr., Ph.D. Senior Vice President, Preclinical Research Development | 280.2K | 93.7K | — | — | — | 1.5K | 375.3K | 0.00% | ↗ |
| 174 | 2004 | James H. Sabry, M.D., Ph.D. Chief Executive Officer | 393.5K | 80.0K | — | — | — | 990.00 | 474.5K | 0.00% | ↗ |
| 175 | 2004 | Robert I. Blum President | 295.0K | 72.0K | — | — | — | 645.00 | 367.6K | 0.00% | ↗ |
| 176 | 2004 | David J. Morgans, Jr., Ph.D. Senior Vice President, Preclinical Research Development | 254.2K | 45.8K | — | — | — | 1.3K | 301.2K | 0.00% | ↗ |
| 177 | 2004 | Andrew Wolff, M.D., F.A.C.C. Senior Vice President, Clinical | 92.5K | 92.7K | — | — | — | 443.00 | 185.6K | 0.00% | ↗ |
| 178 | 2004 | Sharon A. Surrey-Barbari Senior Vice President, Finance | 97.2K | 80.7K | — | — | — | 506.00 | 178.4K | 0.00% | ↗ |
| 179 | 2003 | Robert I. Blum President | 268.4K | 229.4K | — | — | — | 604.00 | 498.4K | 0.00% | ↗ |
| 180 | 2003 | James H. Sabry, M.D., Ph.D. Chief Executive Officer | 354.2K | 104.4K | — | — | — | 1.0K | 459.6K | 0.00% | ↗ |
| 181 | 2003 | David J. Morgans, Jr., Ph.D. Senior Vice President, Preclinical Research Development | 243.1K | 51.8K | — | — | — | 1.2K | 296.1K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
| Filing date | Form type | Filing |
|---|---|---|
| 2026-04-17 | DEF 14A | ↗ |
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert I. Blum | Chief Executive Officer, President & Director | 2M | male |
| Fady Ibraham Malik FACC | Executive Vice President of Research & Development | 985.4K | — |
| Andrew Callos | Executive Vice President & Chief Commercial Officer | 902.9K | male |
| Sung H. Lee | EVP & CFO | 886.0K | male |
| Jeffrey J. Hessekiel | Executive Vice President, Chief Legal & Administrative Officer | 286.2K | male |
| James H. Sabry | Co-Founder & Chairman of Scientific Advisory Board | 41.5K | — |
| James A. Spudich | Co-Founder & Member of Scientific Advisory Board | 21.9K | — |
| Jeff Lotz | Vice President of Sales & Operations | — | male |
| Steven Cook | Senior Vice President of Global Supply Chain Operations & Technical Operations | — | male |
| Holly Laughlin | Vice President of Accounting & Corporate Controller | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2025-10-09 | 2025-11-18 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-06-17 | 2025-08-13 | Lisa McClain | MI09 | Spouse | Sale (Full) | $1,001 - $15,000 | ↗ |
| 2025-06-11 | 2025-08-13 | Lisa McClain | MI09 | Spouse | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CYTK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
